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ABSTRACT OF THE DISSERTATION 
Elucidation of Emergent Regional Mechanisms of Heart Muscle Dysfunction in the Mouse 
Model of Duchenne Muscular Dystrophy 
By 
Ya-Jian Cheng 
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2014 
Professor Samuel Wickline, Chair 
 
Cardiac dysfunction is a primary cause of mortality in Duchenne Muscular Dystrophy (DMD), 
potentially related to elevated cytosolic calcium. However, the regional versus global functional 
consequences of cellular calcium mishandling have not been defined in the whole heart. Here, we 
elucidate, for the first time, loci- and age-dependencies between calcium mishandling and myocardial 
sheet function as a manifestation of dystrophin-deficient cardiomyopathy. We also map calcium transients 
to illustrate the regional dependence of ion flux disturbances in the dystrophin-deficient (mdx) mouse 
heart.  Furthermore, we elucidate abnormalities in autophagic processes that can be corrected with 
nanoparticle therapeutics delivering rapamycin to heart tissues to improve ventricular function in affected 
older mice with incipient cardiomyopathy.  We conclude that the rapid reversibility of functional defects 
by reducing cytosolic calcium or by impacting impaired autophagy points to the significance of regional 
mechanical factors in the progression of the disease. 
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Chapter 1: Introduction 
 
 
1.1. Duchenne Muscular Dystrophy 
1.1.1. The Gene 
Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic disease that affects 
1:3500 of newborn boys who manifest unremitting deterioration of all muscle groups over time.  
The symptoms appear at the age of 2–6 years. By the age of 10, untreated patients are usually 
wheelchair-bound, and in their 20s they typically succumb (Fairclough, Wood et al. 2013). 
The cause of DMD is the near or complete absence of dystrophin protein. The dytrophin 
gene is located on chromosome X and is 2.3 million base pair (bp) long (Altamirano, Lopez et al. 
2012), occupying ~0.08% of the human genome of 2.9 billion bp (Alloatti, Gallo et al. 1995). It 
is the longest known human gene (Table 1). The 79 dystrophin exons are spliced into a 14 kbp 
mRNA1, which requires 16 hours for processing in cultured myogenic cells (Altamirano, Lopez 
et al. 2012). Although gene therapy has been suggested as a possible cure for the disease, the 
large size of dystrophin gene exceeds the packaging capacity of currently available viral vectors. 
Although micro-dystrophin (~30% of original dystrophin cDNA sequence) and Dp71 isoform 
(~16% length or full dystrophin) were used to tackle the transfection capacity limitation, the 
effectiveness for this particularly large gene is yet not proven (Nicolas-Metral, Raddatz et al. 
2001; Hecht, Adams et al. 2011; Spurney 2011). Moreover, immune reactions against the 
transfected gene challenge the clinical application of gene therapy (Berry, Andruszkiewicz et al. 
2013).  
                                                          
1 A gene contains exon(s) and usually intron(s). Exons are encoded into mRNA while introns are removed by RNA 
splicing. 
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 Histone H1a Dystrophin Titin 
DNA length 781 bp 2    M bp 293  k bp2 
mRNA length 781 bp 14  k bp 80    k bp2 
Protein M.W. 22 k Da3 427 k Da4 3     M Da5 
Table 1. Example of sizes of genes and proteins in the human genome. Histone H1a is small and 
contains no intron. In the human genome, dystrophin is the largest gene, most of which 
comprises introns. The titin gene produces the largest single protein in human genome. 
  
Interestingly, both titin, the largest mammalian protein (Han, Grounds et al. 2006), and 
dystrophin, the longest gene in humans, exert a significant mechanical role in the heart. Titin is 
considered a mechanical spring responsible for diastolic recoil. The size might reflect the 
mechanical load it bears. Dystrophin is an adaptor between extracellular matrix and cytoskeleton. 
Its gene length reflects the fact that it produces many isoforms, which require alternative splicing 
and regulatory functioning of introns. When promoter defects or nonsense mutations, 
duplications, and deletions lead to complete absence of dystrophin, the resultant disease is DMD.  
When in-frame deletions or other mutations lead to low expression or low function of dystrophin 
protein, the resultant disease is Becker muscular dystrophy (BMD), a milder form of DMD 
(Bowles, McPhee et al. 2012). Figure 1 illustrates the spectrum of mutations and phenotypes for 
the dystrophin gene.  
                                                          
2 Franco-Obregon, A. and J. B. Lansman (2002). "Changes in mechanosensitive channel gating following mechanical 
stimulation in skeletal muscle myotubes from the mdx mouse." The Journal of physiology 539(Pt 2): 391-407. 
3 http://www.ncbi.nlm.nih.gov/protein/NP_005316.1 
4 Monaco, A.P., Neve, R.L., Colletti-Feener, C., Bertelson, C.J., Kurnit, D.M., and Kunkel, L.M. (1986). Isolation of 
candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323:646-650. 
http://www.dmd.nl/isoforms.html 
5 "ProtParam for human titin". ExPASy Proteomics Server. Swiss Institute of Bioinformatics. 
http://web.expasy.org/cgi-bin/protparam/protparam1?Q8WZ42@1-34350@ 
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--- 
Figure 1. Schematic representation 
of dystrophin gene taken from He 
et al (He, Yi et al. 2013) (A), 
protein isoforms (B), dystrophin 
mutational spectrum (C). (A) The 
dystrophin gene is depicted as a 
2500 kb arrow pointing from the 
centromere to the telomere, 
promoters are shown as right-
angled arrows coming off the 
main arrow with a letter depicting 
promoter name and dystrophin 
protein (Dp) in kDa as a number. 
B, brain promoter (Nudelet al., 
1989); M, muscle promoter 
(Klamut et al., 1990); P, purkinje 
promoter (Gorecki et al., 1992); R, 
retina promoter (D'Souza et al., 
1995); B=K, brain and kidney 
(Lidov et al., 1995); S, Schwann 
cell (Byers et al., 1993); G, 
general giving rise to both Dp71 
(Bar et al., 1990) and Dp45 
(Tinsley et al., 1993). (B) Key followed by schematic representations of the various translated 
products from the dystrophin gene. Key: ABS, actin-binding sites 1±3, 4 and 5, WW, WW 
domain; EF, EF hand calcium-binding domain; ZZ, ZZ zinc finger domain; DCC, predicted 
dimeric coiled coil. Protein schematics are shown aligned under the key with different shaped 
regions depicting the different domains. Alternatively spliced exons are shown in black and as a 
square-bracketed 18 below the C terminus of full-length dystrophin, indicating the 18 alternative 
splice variants in this region (see Fabbrizio et al., 1994, for review). 
 
1.1.2. The Protein 
Dystrophin is expressed in muscle, kidney, brain and other human tissues (Chelly, 
Kaplan et al. 1988). In muscle, the dystrophin protein is a physical adapter between extracellular 
matrix (ECM) and intracellular cytoskeleton (Figure 2). Based on stoichiometry, Ghate et al have 
shown that one dystrophin binds directly to 24 actin monomers (Ghate, Baker et al. 2011). 
Dystrophin binds to ECM indirectly through dystroglycans and sarcroglycans. Mutations on 
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dystroglycans and sarcroglycans both lead to distinct forms of muscular dystrophies (Medvedev, 
Murro et al. 2011). Baron et al have shown that the sarcolemma of the dystrophin-deficient (mdx) 
mouse muscles is four time less stiff than that of control mice (Baron, Hecht et al. 2011), 
indicating a mechanical role for dystrophin.  
The absence of dystrophin results in alteration in membrane structure, which is related to 
the dystrophin-associated proteins. The dystrophin-associated protein complex is part of a riblike 
lattice structure called the costamere.(Olamaei, Cheriet et al. 2010). These anchor the 
cytoskeleton to the ECM (Rybakova, Patel et al. 2000), and distribute contractile forces 
generated in the muscle fiber laterally through the sarcolemma to the basal lamina in ECM and 
thereby maintain uniform sarcomere length along the fiber (Danowski, Imanaka-Yoshida et al. 
1992). Absence of dystrophin protein leads to complete loss of the dystrophin-associated protein 
complex and disruption of costamere lattice, resulting in excessive membrane fragility 
(Rybakova, Patel et al. 2000). In addition to these mechanical functions, signaling functions of 
dystrophin have been theorized as discussed in Chapter 4. 
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Figure 2. The dystrophin protein in muscle linking the internal cytoskeleton to the extracellular 
matrix. From (Morelli, Runge et al. 2011) 
 
 
 
1.1.3. The Disease Phenotype 
DMD patients manifest skeletal muscle weakness and fat/fibrosis infiltration in their first 
decade and succumb to respiratory or cardiac failure before the third decade (He, Yi et al. 2013). 
DMD skeletal muscle biopsy characteristically reveals necrotic and degenerating muscle fibers, 
surrounded by macrophages and CD4+ lymphocytes. Smaller immature centrally nucleated 
fibers reflect ongoing muscle cell regeneration (Deconinck and Dan 2007). Raised levels of 
muscle enzymes (CK) in DMD patients offer evidence of sarcolemma fragility that occurs after 
exercise (Stepkowski 2003; O'Brien, Stinson et al. 2008). Subsequent skeletal muscle necrosis 
and fibrosis result in loss of contractility, eventually in respiratory failure, and ultimately death 
from muscle weakness. Monitoring of the disease progression with MRI (Magnetic Resonance 
Imaging) can define regional heterogeneity among various muscle groups, and assess treatment 
efficacy for limiting fatty infiltration and fibrosis (Kim, Laor et al. 2010; Kim, Laor et al. 2010). 
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Histological analysis of DMD hearts demonstrates replacement of myocardium by connective 
tissue or fat (Schmidt, Burmeister et al. 2003). Fibrosis and diastolic dysfunction precede overt 
dilated cardiomyopathy (DCM), which is subsequently complicated by heart failure and 
arrhythmia (Judge, Kass et al. 2011). In DMD patients, the basal posterior-lateral wall is mostly 
affected by fibrosis, sparing the apex, RV, and atrium. However, even under these circumstances, 
heart failure may be induced by stress testing in the face of normal cardiac function at rest 
(Sethna, Rockoff et al. 1988; Schmidt, Burmeister et al. 2003). 
Cardiac dysfunction accounts for 10~20% mortality in DMD, making it the second 
leading cause of patient death after respiratory failure (Gulati, Saxena et al. 2005). Cardiac 
dysfunction develops later than does respiratory dysfunction, but advances in respiratory support 
and patient care have allowed patients to survive into their late 20s and 30s or ordler. (Ishikawa, 
Bach et al. 1999; Ahuja, Kalra et al. 2000; Wagner, Lechtzin et al. 2007) Accordingly, cardiac 
complications now are commanding closer scrutiny in the management of advanced disease in 
DMD patients (Finsterer and Stollberger 2007; McNally 2008; Hermans, Pinto et al. 2010; 
Romfh and McNally 2010). 
The early manifestations and functional consequences of DMD cardiomyopathy have 
been summarized recently by Judge et al in (Judge, Kass et al. 2011): 
The cardiomyopathy that develops in DMD is characterized by normal or 
thinned left ventricular (LV) wall thickness and progressive decline in 
ejection fraction or fractional shortening. Variable degrees of LV dilation 
occur. Abnormal LV relaxation 6  has also been identified as an early 
manifestation in DMD. 
 
                                                          
6 This abnormal relaxation presages the experimental results in section 2.5 showing that cardiac sheet function is 
normal in systole but abnormal in diastole. 
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 Notably in DMD, cardiac diastolic dysfunction precedes systolic dysfunction, as 
observed by Doppler ultrasound (Markham, Michelfelder et al. 2006) and tissue Doppler 
ultrasound (Bahler, Mohyuddin et al. 2005). DMD cardiomyopathy also exhibits regional 
abnormalities: MRI scar imaging detects early onset of fibrosis at the epicardium of the more 
basal segments (Toyota, Fujimoto et al. 2002; Yilmaz, Gdynia et al. 2010). MRI tagging 
methods have revealed abnormal strain at the base but not the apex in patients with normal 
ventricular function (Ashford, Liu et al. 2005) as a manifestation of occult cardiac dysfunction. 
Mertens et al. reported significantly decreased early diastolic myocardial velocities in the 
anterolateral and inferolateral left ventricular walls with normal global systolic function (Mertens, 
Ganame et al. 2008). The previous work by Dr. Wickline’s group using MR tagging uncovered 
occult abnormal wall strains occurring regionally at the base of heart in DMD patients (Ashford, 
Liu et al. 2005) has been supported by subsequent reports by Li et al suggesting that cardiac 
mechanical strain abnormalities are more prominent in the basal segments of hearts in mdx mice 
(Li, Liu et al. 2009). These studies indicate that regional myocardial dysfunction precedes global 
systolic dysfunction and validates the importance of advanced imaging techniques as tools for 
early delineation of DMD cardiomyopathy. 
 
The observed regional dependencies for DMD cardiac mechanical dysfunction remain to 
be explained, as the mutation is present in all cardiomyocytes (Bulfield, Siller et al. 1984; van 
Deutekom, Bremmer-Bout et al. 2001; Banks and Chamberlain 2008).   
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1.1.4. Treatment Options 
Unfortunately, there is no effective curative treatment, but palliative therapy has 
advanced in clinical trials over the last 20 years. To date, the only active pharmacologic 
interventions proven beneficial for the altering the natural history of the underlying dystrophic 
process have been the corticosteroids:  prednisone and deflazacort (Rinaldi, Mayer et al. 2013). 
Both medications have been shown in clinical trials to lead to modest improvements in muscle 
strength and function, although the duration of these benefits typically lasts less than 2 years and 
the mechanism remains undefined (Araujo, Bonuccelli et al. 2013; Hollinger, Gardan-Salmon et 
al. 2013). Importantly, azathioprine (an immunosuppressant) and prednisone both decrease DMD 
muscle inflammatory infiltrates equally, but only prednisone improves strength (Griggs, Moxley 
et al. 1991; Kissel, Lynn et al. 1993). Animal studies have shown that prednisone enhances 
strength in dystrophin deficient transgenic mice that lack T-cells and B-cells, indicating 
prednisone’s therapeutic effect does not operate through T-cell/B-cell immune suppressive 
pathways (Golumbek, Keeling et al. 2007). 
β-adrenergic receptor blockers, angiotensin-converting enzyme inhibitors (ACEi) and 
angiotensin II-type 1 receptor blockers (ARBs) are also used for treating DMD cardiomyopathy 
(Duboc, Meune et al. 2007; Ogata, Ishikawa et al. 2009; Fayssoil, Nardi et al. 2010). Our group 
has demonstrated a beneficial effect of ACEi on reducing fibrosis and calcium content in Syrian 
hamster with cardiomyopathy, which harbors a related sarcoglycan deficiency. Although the 
precise mechanism is unclear, a 10 year long clinical study showed that ACEi reduces DMD 
mortality (Duboc, Meune et al. 2007). A large body of work on ACEi for scar tissue reduction 
has demonstrated utility for inhibiting focal and global cardiac remodeling after myocardial 
infarction by interrupting angiotensin signaling in the heart (Iwata, Cowling et al. 2011). 
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1.1.5. The mdx mouse model 
Animal models are valuable tools for studying the pathogenesis of disease and for pre-
clinical trials. The mdx mouse is the most widely utilized animal model for DMD (Williams and 
Allen 2007; Banks and Chamberlain 2008). It carries a point mutation leading to complete 
absence of dystrophin in myocytes. Similar to the later onset of cardiomyopathy in human 
patients, young mdx mice (< 3 months old) develop only a mild phenotype of cardiac disease and 
exhibit normal resting [Ca2+]I (Williams and Allen 2007; Van Erp, Loch et al. 2010). However, 
both dilated cardiomyopathy and elevated resting [Ca2+]i begin to be observed by about 10 
months of age (Quinlan, Hahn et al. 2004; Williams and Allen 2007).  Since mdx mice share the 
same genetic defect as DMD patients, they represent a standard model for assessing cardiac 
dysfunction and therapeutics.  
 
1.1.6. Calcium Overload Hypothesis 
With respect to pathophysiological features of dystrophin deficiency potentially 
responsible for mechanical dysfunction, several recent studies in isolated cardiomyocytes of mdx 
mouse have suggested that intracellular calcium ([Ca2+]i) mishandling is a key causative factor 
(Williams and Allen 2007; Fanchaouy, Polakova et al. 2009; Allen, Gervasio et al. 2010). Data 
acquired from mdx mice showed elevated resting [Ca2+]i in dystrophin-deficient cardiomyocyte 
(Pressmar, Brinkmeier et al. 1994; Williams and Allen 2007). The calcium overload activates 
calpains to promote proteolysis leading to cardiomyocyte degeneration (Spencer, Croall et al. 
1995; Spencer and Tidball 1996; Gailly, De Backer et al. 2007). The calcium mishandling might 
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also affect the cardiac contraction that is controlled by calcium induced calcium release 
(Bellinger, Reiken et al. 2009).  
Specifically, (Sapp, Bobet et al. 1996) reported that under 1 Hz pulse stimulation, peak 
force and time-to-peak force were similar in both mdx and wildtype cardiac fibers, but half-
relaxation time was significantly prolonged in mdx, indicating normal contraction but abnormal 
relaxation. However, (Alloatti, Gallo et al. 1995; Janssen, Hiranandani et al. 2005) both reported 
depressed contractile force in mdx cardiac fiber, as compared to wildtype. This reported disparity 
in normal versus abnormal contractile force might be a consequence of a higher stimulation 
frequency used by Alloatti (4 Hz) and Janssen (2.8Hz). Nicolas et al reported abnormally 
prolonged relaxation in mdx skeletal muscles, while the active contraction metrics were normal 
(Nicolas-Metral, Raddatz et al. 2001), suggesting a decreased capacity for calcium removal in 
mdx cells leading to alterations of muscle relaxation that accords with the observation that 
diastolic dysfunction precedes systolic dysfunction in DMD patients and mdx mice (section  
1.1.3). 
Several mechanisms for elevated resting [Ca2+]i have been proposed, offering 
opportunities for developing new therapies. One promising therapeutic approach is to inhibit the 
calcium influx that occurs through SAC (stretch activated channels) or through transient 
microruptures of the sarcolemma. It is well recognized that mdx cardiomyocytes are sensitive to 
stretch induced injury that is correlated with increased resting [Ca2+]i (Lynch 2004; Yeung and 
Allen 2004). Inhibition of SAC or the application of the membrane sealant poloxamer 188 
reduces resting [Ca2+]i and prevents injury (Yasuda, Townsend et al. 2005; Whitehead, Streamer 
et al. 2006; Ward, Williams et al. 2008). In vivo application of poloxamer 188 also protects mdx 
mice from heart failure during dobutamine mediated cardiac challenge (Yasuda, Townsend et al. 
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2005). Inhibiting the leakage of ryanodine receptor (RyR2), a calcium release channel located on 
the sarcoplasmic reticulum, is another emerging therapeutic approach (Bellinger, Reiken et al. 
2008; Shannon 2009). Notably, the RyR2 of mdx cardiomyocytes appears to be hypernitrosylated, 
which prevents RyR2 from fully close at resting state (Bellinger, Reiken et al. 2009). The 
resulting sarcoplasmic reticulum calcium leakage through RyR2 is indicated by the presence of 
calcium sparks (Ward, Schneider et al. 2000). Several 1-4-benzothiazepine derivatives, such as 
S107 and KD201, can stabilize RyR2 to reduce calcium leakage and improve cardiac function 
(Wehrens, Lehnart et al. 2004; Lehnart, Terrenoire et al. 2006). 
Besides pharmaceutical approaches, transgenic approaches provide potential remediation 
of calcium mishandling. The root cause of DMD is the lack of dystrophin, making transgene 
therapy for correction of the dystrophin gene preferable to altering calcium handling genes. 
However, clinical studies suggest that immunity to transgenic micro-dystrophin in DMD patients 
represents a significant challenge, because patients that are dystrophin-null recognize transgenic 
micro-dystrophin as an exogenous antigen (Mendell, Campbell et al. 2010). Therefore, 
transgenic strategies based on endogenous genes, such as sarco/endoplasmic reticulum Ca2+-
ATPase (SERCA), may offer an immune advantage as compared to dystrophin gene therapies. 
Indeed, cardiac SERCA2a gene transfection has been shown to correct ECG abnormalities in 
heart (Shin, Bostick et al. 2011); and skeletal SERCA1 gene transfection corrected skeletal 
muscle calcium reuptake in dystrophic mice (Goonasekera, Lam et al. 2011). 
The previously reported lack of efficacy of L-type calcium channel blockers against 
DMD associated muscular dystrophy should not negate the potential value of calcium channel 
targeted therapy (Phillips and Quinlivan 2008). L-type calcium channels regulate calcium inflow 
upon depolarization and are closed in the resting state. Since calcium leakage through these 
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channels has not been reported, L-type calcium channels’ effect on regulating resting [Ca2+]i 
should not be expected to be significant.  
In summary, calcium targeted therapy holds potential for treating DMD. Because calcium 
influx cannot be measured in vivo in heart tissue, we propose that development of a surrogate 
cardiac phenotype that reflected [Ca2+]i would be useful for evaluating the efficacy of treatment.  
We have previously shown that left ventricular myocardial architecture changes dynamically in 
cardiac cycle due to calcium regulated contraction-relaxation (Chen, Liu et al. 2005).  
 
1.1.7. Hypothesis 
How calcium mishandling influences cardiac mechanical dysfunction in whole heart 
preparations has not been clarified, especially taking into account cellular and mechanical events 
that are spatio-temporally distributed and regionally heterogeneous (DeAnda, Komeda et al. 
1998; Balzer, Furber et al. 1999). Given the recognized abnormal and regionally heterogeneous 
wall strains (Figure 3) and fibrosis (Ashford, Liu et al. 2005; Yilmaz, Gdynia et al. 2008; Yilmaz, 
Gdynia et al. 2010) in DMD hearts of both human patients and mdx mice, we hypothesize that 
the sheet functional consequences of dystrophin deficiency plays out regionally in DMD hearts 
over time despite the ubiquitous lack of dystrophin protein in all cardiomyocytes. We 
hypothesize that elevated resting [Ca2+]i directly affects myofiber and sheet kinetics in mdx 
mouse hearts which can be quantified by diffusion tensor MRI (DTI, Chapter 2). 
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Figure 3. Cardiac MRI detected 
abnormal strain at base but not 
apex of DMD patient hearts, 
indicating base exhibits more 
myocardial dysfunction than 
apex. Figure from (Ashford, 
Liu et al. 2005) 
 
 
 
The heart comprises a syncytium of cardiomyocytes that are organized in unique 3D fiber-
sheet architecture that is critical for optimizing a coordinated sequence of excitation, contraction, 
and relaxation (Streeter and Hanna 1973; Costa, Takayama et al. 1999). Many reports have 
shown that sheet function produces a sliding motion that is accompanied by dynamic 
reorientation in systole, contributing to approximately 50% of focal wall thickening (LeGrice, 
Smaill et al. 1995; LeGrice, Takayama et al. 1995; Costa, Takayama et al. 1999; Dou, Tseng et 
al. 2003; Chen, Liu et al. 2005). Significant sheet-fiber deformation was also found in early 
diastole (Ashikaga, Criscione et al. 2004). Because one role of dystrophin is to anchor 
cardiomyocytes to the extracellular matrix to coordinate contraction-relaxation coupling, we 
propose that dystrophin deficiency could adversely affect sheet function. Given that ventricular 
wall strain vary regionally from base to apex, and in light of the expected vulnerability of 
dystrophin deficient cardiomyocytes to stretch-induced membrane injury, we sought to examine 
the role of sheet function in the regional mechanical defects reported in the DMD 
cardiomyopathy (Ashford, Liu et al. 2005; Li, Liu et al. 2009). We investigated the heart sheet 
structure defect in regions of heart with ultra high-field MRI, because MRI is non-destructive 
and provides functional assessment according to the methodology described in Chapter 2. 
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Examination of this regional structural functionality may add to the fundamental understanding 
of the nature of the heart dysfunction in DMD and lead to improved early monitoring of 
interventions designed to salvage cardiac structure and function. 
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Chapter 2: MRI for Cardiac Sheet Function 
 
2.1. Cardiac muscle structure 
The normal architecture of the heart muscle remains elusive despite recent advance in high 
resolution images offered by MRI and photoacoustic imaging (Gilbert, Benson et al. 2007). 
Several models have been proposed to explain cardiac structure without reaching a consensus. 
Therefore, accurate knowledge about the architecture of heart muscles is critical in 
understanding normal heart and cardiomyopathy. A comprehensive understanding of myocardial 
architecture would help us to (1.) explain cardiac electric and mechanical mechanics; (2.) 
simulate cardiac physiology; (3.) design intervention/monitoring strategy; and (4) understand 
structure-function relationship of the heart. In the future, we could compare myocardial 
architecture among fish, amphibian, reptile, bird, and mammal, to understand the evolution of the 
heart, in which lies the natural history of how the heart adapts the gravity and land environments 
with high pressurizing ability. A comprehensive review of cardiac architecture during 17th 
century and year 2002 can be found in a MIT doctorate dissertation (Dou 2002). Below is my 
review of recent update.  
 
2.1.1. Fiber 
Myocardial fibers are cardiac muscle cells, which include sarcolemma and bundles of 
parallel or sometimes branching myofibrils. Cell and fiber are terms that may be used 
interchangeably (Pollack 1990). The 3D myocardial architecture is critical for optimizing a 
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coordinated sequence of excitation, contraction, and relaxation (Streeter and Hanna 1973; Costa, 
Takayama et al. 1999). The earliest study of fiber helical path was a reprint in Latin by Stensen 
in 1664. An English review can be found in (Dou 2002).  
Based on laborious histology work, Streeter reported a smooth transition of fiber helix 
angle (α, angle between fibers and local circumferential axis) in the transmural direction (Figure 
4) Streeter proposed a wicker basket model to explain how α might reflect the ventricular volume 
(Figure 4 B). However, the basket model represents the LV incorrectly, because recent studies 
have found that helix angle decreases during longitudinal extension (i.e., diastole) (Chen, Liu et 
al. 2005). In contrast, the wicker basket model predicts increased α during longitudinal extension 
(Figure 4 B). Nevertheless, a smooth transmural transition of α is observed in many mammalian 
species (Scollan, Holmes et al. 1998; Tseng, Wedeen et al. 2003; Chen, Liu et al. 2005; Helm, 
Beg et al. 2005). Chen 2005 found that Δα is decreased by ~7 degree in diastole compared to 
systole. This small change was not detected by Streeter with his histology method (Streeter and 
Hanna 1973), probably due to the unavoidable dehydration/deformation artifacts of histology 
specimen preparation.  
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Figure 4. A. Cartoon of LV fiber orientation from (Streeter and Hanna 1973). Green: epicardial 
fiber, left handed helix. Blue: midcardial fiber, circumferential. Red: endocardial fiber, right 
handed helix. B. Streeter’s proposed wicker basket model of helix angle change between diastole 
and systole. 
 
2.1.2. Sheet 
Robert Grant conceived and illustrated how fibers might aggregate into a laminar sheet 
structure (Grant 1965) (Figure 5). But the laminar sheet structure was not actually visualized 
until 1995 by LeGrice using the histology method (LeGrice, Smaill et al. 1995). The discovery 
of the myocardial sheet exemplified how an obvious structure eluded scientists for a long time. 
All of the popular experimental mammalian hearts exhibit laminar structures, similar to layers of 
muscle found in a fish fillet (Figure 6). Myocardial sheet is about four layers of fibers 
aggregating into a laminar structure (simply called a “sheet” in this thesis). Figure 7 shows the 
sheet architecture in a fresh, unfixed and unstained mouse left ventricle (Zhang, Cheng et al. 
2012). Figure 7 is acquired with advanced photoacoustic microscopy (PAM) system. The 
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significances of the PAM image of myocardial sheet are (1) it is the highest resolution of unfixed 
sheet to the best of my knowledge; (2) the heart is unfixed, meaning there’s minimal dehydration 
artifacts compared to formalin fixed hearts; (3.) it requires no staining nor contrast agent, saving 
time and artifacts of doing so; (4) it is a three dimensional imaging modality, suitable for 
investigating the 3D structure like the heart muscle. For technical details, please refer to (Zhang, 
Cheng et al. 2012). 
 
Figure 5. Robert Grant proposed that “planes” can be 
formed by fibers. “Schema of fiber to fiber 
relationship which appears to obtain typically in the 
left ventricle. While fibers are parallel, by their 
branchings they form ‘planes’ which appear to rotate.” 
(Grant 1965) 
 
 
 
 
 
Figure 6. Cooked fish fillet shows sheet structure of 
skeletal muscle of fish, indicating muscle fibers 
aggregate into secondary structure in a form of sheets. 
Cooking helps the separation of sheets, indicating the 
connective tissues between sheets are more vulnerable 
to thermal denaturation. The major difference between 
fish sheet and mammal myocardial sheet is in the fish, 
fiber is parallel to sheet normal direction. In contrast, in 
myocardial sheet, fiber is perpendicular to the sheet 
normal direction.   
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Figure 7. Photoacoustic microscopic (PAM) image of a unfixed, unstained, and un-dehydrated 
myocardium, showing sheet structure of a mouse left ventricle. (a), PAM image of the left 
ventricle free wall (FW) marked in (c) acquired at 532-nm wavelength. (b), Close-up PAM 
image. The boundaries of the branching sheets are apparent. Red dashed line: long axis. Yellow 
dashed-dot line: sheet boundary. (c), Photograph of the heart specimen. LV, left ventricle; RV, 
right ventricle. (Zhang, Cheng et al. 2012). 
 
Here is a chronicle summary of important discovery on sheet. After LeGrice visualized 
the sheets with histology (LeGrice, Takayama et al. 1995), Costa and Chen inferred that sheet 
shearing contributes dominantly to heart wall thickening using radiocinegraphy and DTI, 
respectively (Costa, Takayama et al. 1999; Chen, Liu et al. 2005). Using diffusion tensor MRI 
on alive human subjects, Dou reported that sheets change orientation in cardiac cycle (Dou, 
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Tseng et al. 2003). Specifically, sheets align closer to short axis in systole than diastole. Using 
confocal histology, Pope reported that sheet presents dominantly at mid- and endocardium but 
not at epicardium (Pope, Sands et al. 2008). Using 9.4T MRI with 3 day long scan time, Gilbert 
confirmed Pope’s finding whith the field of view of a whole heart, revealing more mysterious 
helical nature of sheets in high resolution (25µm) (Gilbert, Benoist et al. 2012). Readers are 
directed to view the spplemental movie in Gilbert’s paper for the 3D whole heart sheet structure. 
 
2.1.3. Nomenclature of  the heart segments 
Figure 8 illustrates the terminology used to describe the various regions of the heart. This 
terminology follows AHA consensus (Cerqueira, Weissman et al. 2002).  
Figure 8. Left ventricle (LV) is rounded in shape in short axis view. Right ventricle (RV) has a 
semilunar shape. Aorta and vena cava are closer to the heart base than the apex. Apex is pointing 
to the left in normal human chest. Heart base is physically closer to the head and has larger 
diameter than apex. 
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2.2. Diffusion Tensor MRI 
2.2.1. Background 
MRI modulates magnetic field to affect nuclear spins to form images (Appendix). Under 
magnetic gradient, the diffusion of molecules dephases the nuclear spins and thus decreases MR 
signal. DTI (Diffusion Tensor MRI) quantifies the ADC (apparent diffusion coefficient) from the 
signal decay. Specifically, the DTI signal predominantly comes from nuclear spins of water 
protons. In spin echo imaging, the signal intensity is governed by eq1. 
      𝑆 = 𝑃𝐷(1 − 𝑒−𝑇𝑅/𝑇1) 𝑒−𝑇𝐸/𝑇2 𝑒−𝑏𝐷                                                                              (eq1) 
S is signal intensity, PD is proton density, T1 and T2 are relaxation (decay) times of protons 
within the samples under given B0. D is the ADC, which represents the observed Brownian 
motion of water molecules in tissue. TR and TE are repetition time and echo time. b is the 
diffusion-weighing factor with units of s/mm2. From eq1, one can see higher b value decreases S  
(Basser 1995).  
TR, TE and b can be adjusted on the scanner. Longer TR and shorter TE generate better 
signal to contrast ratio (SNR) but require longer scan time and faster responding electronics, 
which are both more expensive. Tradeoff was made between SNR and scan time. We want D for 
the diffusion information in it, but it is impossible to calculate the D with just one S in eq1. 
Therefore Stejskal and Tanner devised the two-S method to calculate the D (Stejskal 1965). See 
equations below: 
𝑆1 = 𝑃𝐷 (1 −  𝑒
−
𝑇𝑅
𝑇1) 𝑒−
𝑇𝐸
𝑇2  𝑒−𝑏1 𝐷 = 𝑆0 𝑒
−𝑏1 𝐷                            …….measurement 1                           
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𝑆2 = 𝑃𝐷 (1 −  𝑒
−
𝑇𝑅
𝑇1) 𝑒−
𝑇𝐸
𝑇2  𝑒−𝑏1 𝐷 = 𝑆0 𝑒
−𝑏2 𝐷                               …….measurement 2                           
𝑆2
𝑆1
= 𝑒−( 𝑏2− 𝑏1) 𝐷                (eq2) 
Rearranging eq2, we obtain: 
     𝐷 = − ln (
𝑆2
𝑆1
) /( 𝑏2− 𝑏1)
              (eq3) 
That is, we can derive a scalar D by attenuating the signal with two different b values. For 
example, I have used b1= 0, and b2=800  (s mm
-1) in my work.  
 
2.2.2. Restricted Diffusion 
Brownian motion of water molecule in an isotropic diffusion environment is 
characterized by a single parameter, the diffusion coefficient, D. For example, in three-
dimensional space, random walkers spread with time t according to a Gaussian distribution 
would have a mean square displacement, E(x2) = 6Dt. That is, in isotropic diffusion environment, 
D is the same in all direction. However, complexity in the microscopic structure of myocardium 
restricts water molecular motion anisotropically and results in non-Gaussian diffusion and hence 
different values of D in different directions. Therefore, instead of a single scalar D, multiple Ds 
are required to describe the diffusion anisotropy.  
To detect anisotropic diffusion, one could repeat Stejskal’s two measurements method 
(eq3) in 6 non-collinear directions to fill in the following matrix D: 
𝑫 =
 𝐷𝑥𝑥 𝐷𝑥𝑦 𝐷𝑥𝑧
𝐷𝑦𝑥 𝐷𝑦𝑦 𝐷𝑦𝑧
𝐷𝑧𝑥 𝐷𝑧𝑦 𝐷𝑧𝑧
        (eq4) 
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The D in eq4 is a 3 x 3 matrix, which is also a rank 2 tensor. For example, Dxx is the ADC in 
x direction. Dxy is ADC in xy direction, which is in the same direction of the vector 
(x,y,z)=(1,1,0). From the diffusion tensor, D, we can assess magnitude of ADC in different 
directions. Specifically, the ADC is found to be the greatest in fiber direction and smaller in 
perpendicular directions. Therefore, the tensor not only provides the orientation information (e.g, 
which direction has the largest ADC) but also relative ratios of ADCs in different directions (i.e., 
anisotropy of the diffusion environment, Chapter 3). The fact that water diffusion is restricted by 
the underlying tissue microstructure provides a unique method of assessing myocardium 
architecture (Safford, Bassingthwaighte et al. 1978; Garrido, Wedeen et al. 1994; Ennis and 
Kindlmann 2006). 
In summary, DTI is an established method for 3D reconstruction of myocardial 
microarchitecture that can depict structural changes across the heart cycle in the intact heart 
(Chen, Liu et al. 2005; Sosnovik, Wang et al. 2009). The value of DTI is it is non-invasive, non-
destructive, 3-dimensional and rapid, compared to traditional histology (Mori and Zhang 2006; 
Roberts and Schwartz 2007).  
 
2.1. Method: DTI for mdx mice cardiac structure 
In the heart, the primary eigenvector is considered to be aligned with the local orientation of 
cardiac myofibers, and thus defines the fiber angle (α) (Hsu, Muzikant et al. 1998; Scollan, 
Holmes et al. 1998; Holmes, Scollan et al. 2000; Geerts, Bovendeerd et al. 2002). The secondary 
eigenvector is aligned parallel to sheet surfaces (Tseng, Wedeen et al. 2003) and thus defines the 
sheet angle (β, Figure 9 A). This definition system is based on the fact that eigenvalues of a 
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diffusion tensor are also the apparent diffusion coefficients describing microscopic diffusion 
movements, which are the largest in the fiber direction and second largest in the sheet direction 
(Scollan, Holmes et al. 1998; Chen, Suzuki et al. 2005).  
Figure 9. Representative DTI and histology images of sheet architecture in WT mouse hearts. A, 
A local cylindrical coordinate system was used to describe LV myocardial structures. The 
primary eigenvector (EV1) of the diffusion tensor is characterized by helix angle (α), which is 
the angle between the circumferential axis and the projection of the first eigenvector onto the 
circumferential-longitudinal plane; the α shown in A is set as negative. The secondary 
eigenvector (EV2) is characterized by sheet angle (β), which is the angle between the secondary 
eigenvector and the radial axis; the β shown in A, toward base and toward endocardium, is set as 
negative. B & C, short-axis views of DTI determined sheet angle () in a basal slice of WT heart 
that was sequentially arrested in diastole (B) and systole (C). The posterior-lateral wall of LV 
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manifested two populations of , exhibiting positive (red) and negative (blue) values. D, 
Histology of sheet organization in a WT heart. Images were acquired from the basal-lateral wall, 
which is highlighted on the H&E stained image (insert). Two populations of  were 
observed.(LV, left ventricle; RV, right ventricle; PA, papillary muscle; P, Posterior; L, Left; R, 
Right; A, Anterior).  
 
 
Experimental Methods 
2.1.1. Langendorff perfusion for DTI 
Animals 
Adult male mdx (C57BL/10ScSn-Dmdmdx/J, N=14) and age matched male wild type 
(WT: C57BL/10SnJ, N=10 and C57BL/6, N=3) mice were purchased from the Jackson 
Laboratory (Bar Harbor, ME, USA) and the National Institute on Aging (NIA, MD, USA)(18) 
and housed under a AAALAC-approved facility to 16-month of age. All mice were housed in the 
same animal facility and cared for under approval by Washington University’s animal study 
committee. All mice were separated into two groups for DTI and optical mapping studies 
described below. 
 
Isolated Heart Preparation for DTI 
Ten mdx mice and ten WT mice were used for both diastolic and systolic DTI 
measurement (Figure 10). Mice were heparinized (1000 U/kg) and anesthetized with isoflurane. 
Hearts were excised and cannulated for retrograde perfusion using a procedure modified from 
(Chen, Liu et al. 2005). Briefly, hearts were first perfused with Krebs buffer at 60 mmHg 
constant pressure for approximately 5 min to wash out the residual blood. Five mdx hearts and 
five WT hearts were perfusion-arrested in diastole (perfusion pressure = 60 mmHg) with regular 
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St. Thomas’ cardioplegic solution containing normal [Ca2+] of 1.2 mmol/L (denoted as mdx-NC 
and WT-NC, respectively) under room temperature.  DTI of diastolic arrested hearts was 
performed for 1.5 hours. After that, hearts were reperfused with 37 ͦC Krebs buffer to resume 
beating. Upon stabilization of contraction (~6 min, up to 300 beats per min), 2.5 mmol/L Ba2+ 
was then introduced to induce systolic cardiac contracture while Ca2+ was lowered to 0.078 
mmol/L (Munch, Comer et al. 1980; Toyota, Fujimoto et al. 2002; Chen, Liu et al. 2005). To 
evaluate the effect of [Ca2+] on diastolic cardiomyocyte architecture in mdx mice, another five 
mdx hearts and five WT hearts were perfusion-arrested in diastole with a modified cardioplegic 
solution containing low [Ca2+] of 0.078 mmol/L (denoted as mdx-LC and WT-LC, respectively). 
The 0.078 mmol/L [Ca2+] was chosen over the calcium-free condition to minimize the risk of 
complete depletion of intracellular calcium, which can cause calcium overload upon reperfusion 
with solutions containing normal [Ca2+], thereby exerting unfavorable effects on certain ion 
channels (Munch, Comer et al. 1980; Robinson and Harwood 1991).  
The systolic arrest of mdx-NC, WT-NC, mdx-LC, and WT-LC (defined below) are all 
achieved with the same modified Tyrode solution containing 2.5 mmol/L Ba2+ and 0.078 
mmol/L Ca2+ (Chen, Suzuki et al. 2005). All solutions were equilibrated with 95% O2 plus 5% 
CO2 (PH 7.4) and contained adenosine (45µmol/L) to maximally dilate the coronary vessels 
(Judd, Rottman et al. 1992).  Bovine serum albumin (BSA; 61 µmol/L) was added to the 
perfusate to minimize interstitial edema (Dunphy, Richter et al. 1999; Watts and Maiorano 1999). 
DTI of systolic contracture hearts were conducted for ~1.5 hours. Upon the completion of MRI, 
all hearts were perfused with 10% formalin for histological study.  
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Figure 10. Flow chart for DTI acquisitions for diastolic and systolic arrested hearts. Left, ten 
mice perfused with normal calcium (NC) concentration for diastolic arrest then high barium for 
systolic arrest. Right, ten mice perfused with low calcium concentration (LC) for diastolic arrest 
then high barium for systolic arrest. See text for details. 
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2.1.2. Perfusion compatible MR Coil 
A dedicated MRI-compatible retrograde mouse heart perfusion system was made. This 
system provides a quantitative and non-destructive assessment of diastolic and systolic 
myocardial architecture from the same heart. The system includes: (1) a custom-built 15 mm-
diameter solenoid coil, which provides high SNR: 65 for non-diffusion weighted images and 40 
for diffusion weighted images (See Figure 11 for the coil design.); (2) a Langendorff constant-
pressure perfusion apparatus. The constant perfusion pressure is controlled by a reservoir with 
constant height. Perfusate efflux was removed by vacuum suction. The heart was contained in a 
plastic tube made by syringe, which is omitted in Figure 11 for simplicity but is important to 
prevent contact between perfusate and the copper coil. A variable capacitor was soldered at the 
center of the gap of the single turn copper coil for resonance frequency tuning. The distance, h, 
between the cable loop and the copper coil determines the coefficient of coupling, k, which 
determines the mutual inductance, L.  
    𝐋 = k√𝐿1 𝐿2 , k is between 0 (when h is large) and 1 (when d is small)             (eq5) 
 
The Figure 11 B is an equivalent circuit of my coil. The resonance frequency, 𝒇, of the 
circuit can be determined by series RLC resonator. Practically, L and C were adjusted to 
resonate at 499.70 MHz for the 11.7 tesla ultra-high field MR scanner used in this study. 
𝑓 =
1
√𝐿𝐶
             (eq6) 
 
29 
 
Figure 11. A. Cartoon of single turn 
solenoid coil and perfused mouse heart 
setup. A plastic tube containing the heart 
and preventing perfusate from contacting 
the copper coil is omitted for visual 
simplicity. Distance between the cable 
loop and the copper coil is denoted by h. 
B. Equivalent circuit. R is the resistance 
of loading (perfusate and heart) and 
copper. L1 is the inductance of the cable 
loop. L2 is the inductance of the copper 
coil. C is variable capacitor. 
 
 
 
 
 
 
 
 
2.1.3. Imaging parameters 
All MRI experiments were performed on a Varian 11.7 tesla small animal MR scanner 
(Varian Associates; Palo Alto, CA). Long-axis scout images were acquired as previously 
described (Chen, Liu et al. 2005). A multislice spin-echo sequence with diffusion-sensitizing 
gradients were used to acquire short-axis, diffusion weighted images. Diffusion-sensitizing 
gradients were applied in six noncolinear directions. Imaging parameters were as follows: echo 
time, 46 ms; time interval between diffusion-sensitizing gradients, 30 ms; b-value, 0 and 800 
s/mm2; in-plane resolution, 125  125 µm2, repetition time, 3 s; and image-acquisition time, 1 h. 
For diastolic arrested hearts, eight contiguous slices (thickness = 0.7 mm) extending from the 
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base to apex were acquired. For systolic contracture hearts, eight contiguous slices were acquired 
with slice thickness adjusted to 0.55–0.65 mm based on the fraction of longitudinal shortening. 
Attention was paid to keep the slice selection and the heart orientation the same between diastole 
and systole imaging.  
 
2.1.4. Post processing, sheet angle calculation (β)  
All MR images were processed using custom-developed software written in Matlab (The 
MathWorks Inc., M.A., USA) as described previously (Chen, Liu et al. 2005). Specifically, fiber 
helix angle (α) and sheet angle (β) were calculated based on a right-handed helix, the fiber helix 
angle (α) was calculated as the angle between the circumferential cardiac axis and the projection 
of the first eigenvector of the diffusion tensor onto the circumferential-longitudinal plane 
(Scollan, Holmes et al. 1998). Sheet angle (β) was determined as the angle between the 
secondary eigenvector and the radial axis. Sheet inclination toward the base from endocardium to 
epicardium was set as positive (Figure 9 D) (Scollan, Holmes et al. 1998; Tseng, Wedeen et al. 
2003). Because regional wall thickening is accompanied by a reduced magnitude of the sheet 
angle, |β|, therefore |β| was used to analyze sheet function (LeGrice, Takayama et al. 1995; Chen, 
Liu et al. 2005). LV wall thickness was calculated as the mean distance between epicardial and 
endocardial borders. The transmural difference of α, defined as the difference in endocardial and 
epicardial helix angles, i.e., Δα = αendocardium-αepicardium, was used to quantify transmural changes 
of fiber orientation. 
2.1.1. Statistical methods 
Statistical differences were assessed with the analysis of variance (ANOVA) or the 
multivariate analysis of variance (MANOVA) as appropriate. Bonferroni correction was applied 
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to post-hoc comparisons. A value of p < 0.05 was considered significant. Data were expressed as 
mean  standard error of the mean (S.E.). All statistics were conducted with the IBM SPSS 
Statistics program.  
 
2.1.2. Histology 
After DTI acquisition, five mdx and five wildtype hearts were rapidly fixed in 10% formalin. 
Fixed hearts were sliced into four blocks with 2 mm thickness from base to apex. Each slice was 
embedded in paraffin and sectioned at 4 μm thickness. The tissue sections were stained with 
picrosirius red for the identification of fibrosis (Van Erp, Irwin et al. 2006). The extent of 
myocardial fibrosis was quantified from digitized histological images using a thresholding 
algorithm implemented in Matlab. Regions that demonstrate stronger red-to-green ratio in 
picrosirius red staining were considered to represent interstitial fibrosis. The percentage of tissue 
fibrosis was calculated as the ratio of pixels representing fibrotic tissue vs. pixels of the entire 
short-axis slice, and the average value in two adjacent slices was used in analysis. 
 
2.2. Results: Sheet function in 16-month old mdx mouse hearts 
2.2.1. Morphological observation of β with histology and PAM 
DTI, histology, and PAM all show a similar transmural morphological character of sheet, 
that is, a sharp change of β at midmyocardium of basal posterior mid-wall (Figure 12).  
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Figure 12. A & B, representative short-axis view of DTI determined sheet angle ( ) in a basal 
slice of the same WT heart that was sequentially arrested in diastole (A) and systole (B). The 
posterior-lateral wall of LV possessed two populations of , exhibiting positive (red) and 
negative (blue) values. The transmural portion of positive  is increased in systole (compare the 
portions of red-colored pixels under the dashed lines in A & B). The dotted line in B indicates a 
3 population  transition that appears only in systole.  C, Photoacoustic microscopy of long-axis 
view of a freshly half-split WT mouse heart confirmed two populations of  in LV wall. The 
insert showed H&E stained long-axis WT mouse heart slice with the corresponding region of 
photoacoustic image squared. LV: left ventricle. RV: right ventricle. PA: papillary muscle. 
 
2.2.2. 16 month old mdx hearts manifest reversible regional diastolic sheet 
dysfunction 
DTI defined two populations of β with opposite signs in the LV wall of WT and mdx 
mice, as confirmed by several previous reports (LeGrice, Smaill et al. 1995; Tseng, Wedeen et al. 
2003; Chen, Liu et al. 2005; Helm, Beg et al. 2005; Gilbert, Benson et al. 2007; Pope, Sands et 
al. 2008). Under conditions of barium-induced systolic arrest, || value is decreased in systole 
(Figure 9 B&C, Figure 13 A&B), agreeing with in vivo and ex vivo observations (LeGrice, 
Smaill et al. 1995; LeGrice, Takayama et al. 1995; Costa, Takayama et al. 1999; Chen, Liu et al. 
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2005). At each short-axis imaging slice, the slice-averaged systolic || was comparable among all 
groups of hearts (Figure 13 B, p = N.S.).  However, the diastolic || of mdx hearts (mdx-NC) was 
~10° lower than that of WT hearts (WT-NC) at the base when perfused with regular cardioplegic 
solution (p < 0.05, Figure 13 A). The || at the apex of mdx-NC hearts appeared normal (p = N.S. 
compared to WT-NC at each corresponding short-axis imaging slice), demonstrating that 
diastolic sheet dysfunction in mdx hearts occurred focally at the base. By reducing the [Ca2+] of 
the cardioplegic solution to 7% of its regular concentration, a complete and rapid restoration of 
diastolic | β | in mdx hearts (mdx-LC) to normal values was observed. No effect of calcium 
manipulation on WT cardiac sheet function was observed (WT-LC, p = N.S. compared to WT-
NC at each corresponding short axis imaging slice), indicating that the diastolic sheet 
dysfunction in mdx hearts was substantially calcium dependent. These data suggest that even at 
this advanced age, a principle mechanical abnormality in mdx mice likely is associated with 
regionally-dependent incomplete sarcomere relaxation. 
At the base, further regional analysis indicated that the maximal decrease of diastolic |β| 
in mdx-NC hearts occurred in the endocardium. Compared to WT-NC, mdx-NC exhibited 13° 
lower |β| (75° ± 2° vs. 62° ± 3°) in the endocardium (inner 1/3 wall-depth in transmural 
direction); 10° lower |β| (74°± 1° vs. 64° ± 2°) in the midcardium (middle 1/3 wall-depth in 
transmural direction); and 8° lower |β| (68° ± 2° vs. 60° ± 2°) in the epicardium (outter 1/3 wall-
depth in transmural direction) (Figure 13 C). Moreover, in the posterior-lateral wall, the diastolic 
|β| was 51° ± 6° in mdx-NC (Figure 13 F). This value was approximately 20° lower than that of 
mdx-LC (70°± 4°), as well as that of WT-NC (72° ± 4°) or WT-LC (72° ± 6°) groups ( p < 0.05 
for all comparisons. See post hoc multiple comparison in Table 2 in page 107). Together these 
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findings indicate a clear regional and transmural dependence of incomplete relaxation, despite 
the ubiquitous dystrophin mutation. 
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Figure 13. DTI-determined diastolic and systolic |β| in short-axis slices. A, mdx hearts exhibited 
abnormally lower diastolic |β| that was recovered to normal value after reducing [Ca2+] in the 
perfusate. For hearts perfusion-arrested in diastole with normal calcium solution, mdx hearts 
(mdx-NC) exhibited lower |β| than did WT (WT-NC) hearts with the maximal ~10 degree 
difference occurred at the basal region. In contrast, mdx hearts perfused with the low calcium 
solution (mdx-LC) exhibited normal diastolic |β|. Varying [Ca2+] had no effect on diastolic |β| in 
WT hearts (WT-LC). B, systolic |β| exhibited no difference among four groups of hearts. C, 
diastolic |β| in the epicardium, midcardium, and endocardium at the base of WT and mdx hearts.  
In all regions, diastolic |β| of mdx-LC hearts were comparable to that of WT-LC and WT-NC 
hearts, but all are higher than that of mdx-NC hearts. The largest difference in diastolic |β| 
between mdx-LC and mdx-NC was observed in the endocardium. D & E, representative DTI-
determined diastolic |β| maps on short-axis slices at the base of mdx-NC and mdx-LC hearts. The 
lower |β| in mdx-NC heart, indicated by fewer regions with red color, was visually appreciable. F, 
in the posterior-lateral region (the areas enclosed by dashed line in D & E), the diastolic |β| of 
mdx-NC hearts was approximated 20 degree lower than that of mdx-LC hearts and of all WT 
hearts. Data represent mean ± SEM. N = 5 for each group. *, p < 0.05; †, p <0.005 for the 
indicated short axis location.  
 
2.2.3. 16 month old mdx and WT hearts exhibit similar fiber organization and 
function 
Wall thickness and through-wall differences of myofiber helix angle (Δα) were similar 
between mdx and WT mice (Figure 14), suggesting that the major mechanical abnormality was 
confined to sheets rather than fibers. The normal wall thickness agrees with former publications 
(Li, Liu et al. 2009; Stuckey, Carr et al. 2012) 
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Figure 14. Averaged wall thicknesses in each short axis slice are similar in all four groups, in 
both diastole (A.) and in systole (B.) Averaged through-wall myofiber helix angle differences 
(Δα) in each short axis slice are similar in all four groups, in diastole (C.) and in systole (D.). 
Overall, Δα is increased in systole, agreeing with a prior publication  (Chen, Liu et al. 2005). No 
significance was detected in all comparison in each panel. 
 
2.2.4. 3 month old mdx mice exhibit smaller sheet dysfunction, still reversible by 
low calcium perfusion 
The max difference in |β| between mdx-NC and mdx-LC is 6.1˚˚ (p < 0.66, Table 3 in 
page 110) and 9.3˚2.26˚ (p < 0.005, Table 2 in 107), both at base in 3- and 16-month old mice 
respectively (Figure 15), indicating that this [Ca2+]-dependent sheet dysfunction is also loci 
dependent.  
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Figure 15. A. |β| of 3 month old mdx and WT mice under normal calcium (NC) and low calcium 
(LC) perfusion. B. |β| of 16 month old mdx and WT mice under NC and LC perfusion. Data 
represent mean ± SEM. N = 5 for each group. *, p < 0.05; †, p < 0.005 for the indicated short 
axis location.  
 
2.3. Discussion of |β| 
This study shows for the first time that mdx hearts exhibit an abnormal myocardial sheet 
angle magnitude, |β|, in diastole but not in systole. Agreeably, Goldberg reported that DMD 
patients have abnormally slower wall thinning but normal wall thickening in echocardiography 
(Goldberg, Feldman et al. 1980) (Figure 16), indicating that dystrophin affects normal diastolic 
rather than systolic function. Furthermore, regional and intramural gradients of diastolic 
dysfunction (Figure 13 A & C) are evident, primarily in the more basal segments where 
abnormal calcium handling also occurs (Chapter 4).  
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Figure 16. Using 
echocardiography, Goldberg 
has shown that DMD patient 
heart has significantly slower 
wall thinning but normal wall 
thickening, indicating that the 
absence of dystrophin affects 
diastolic function more than 
systolic function, agreeing with 
the DTI measured sheet angle 
data in Chapter 2. Figure from 
(Goldberg, Feldman et al. 1980). 
 
 
These co-localized abnormalities in calcium handling and diastolic calcium-dependent sheet 
dysfunction strongly suggest that features other than the simple absence of dystrophin are critical 
to the evolution of heart failure in DMD. Indeed, it is well recognized that the mechanical defect 
in the dystrophin encoding gene does not independently elicit DMD cardiac dysfunctions such as 
reduced circumferential wall strain (Ashford, Liu et al. 2005), which emerge in a regionally 
heterogeneous fashion over time, and not at all loci where dystrophin is missing. This loci-
dependency agrees with my findings. 
Given that systolic |β| < diastolic |β| (Figure 13 A & B), the observed lower diastolic |β| in 
mdx heart may reflect that cardiomyocytes are not fully relaxed in diastole. We also confirmed 
that this regional diastolic sheet dysfunction in mdx hearts is a likely consequence of cytosolic 
calcium mishandling, because the regional diastolic sheet dysfunction is quickly reversible upon 
perfusion with a lower level of calcium (Figure 13 A, mdx-NC vs mdx-LC). 
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Chapter 3: Anisotropy information in DTI 
3.1. Introduction 
In Chapter 2, I have used orientation information (β) derived from DTI to detect the basal 
myocardial function abnormality. In this Chapter, I sought for the first time to further explore the 
shape information with fractional anisotropy (FA) and mode of anisotropy (mode) to elucidate 
regional abnormal myocardial fiber/sheet shape in mdx mice hearts. Please refer to Chapter 2 for 
DTI background and methods. Refer to Advanced Engineering Mathematics by Erwin Kreysiz 
(9th ed) for tensor matrix properties. 
Each diffusion tensor can be decomposed into three eigenvectors and three corresponding 
eigenvalues. Eigenvectors carry orientation information, while eigenvalues provide anisotropic 
information for the micro-diffusion environment in the voxel (Bahn 1999). A tensor invariant is 
a scalar value calculated from eigenvalues. For examples, trace and norm are wildely used tensor 
invariants in DTI: 
 
𝑡𝑟𝑎𝑐𝑒 = 𝜆1 + 𝜆2 + 𝜆3 = 3 × 𝐴𝐷𝐶, 𝑤ℎ𝑒𝑟𝑒 𝜆1~3 𝑎𝑟𝑒 𝑒𝑖𝑔𝑒𝑛𝑣𝑎𝑙𝑢𝑒𝑠  
………..eq10 
𝑛𝑜𝑟𝑚 = √𝜆1
2 +  𝜆2
2 + 𝜆3
2
 
………..eq11 
 
In an eigenvalue space of a 3-D Cartesians coordinate system, norm is the distance between 
the origin and the point, (λ1, λ2, λ3). Trace is the sum of the coordinates. The trace is three times 
of the quantity of the apparent diffusion coefficient (ADC), which is an effective indicator of 
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stroke-sites in brain (van Gelderen, de Vleeschouwer et al. 1994; Latt, Nilsson et al. 2009). The 
norm is a measure of total magnitude of diffusion (Grant 1965). Trace and norm are both in the 
units of mm2/sec, the same as the unit of eigenvalues. 
For example, fractional anisotropy (FA) and mode are two independent scalar values 
calculated from eigenvalues (Figure 17). FA has been widely used in many DTI measurements 
(Pierpaoli and Basser 1996), especially in the brain (Papanikolaou, Karampekios et al. 2006). 
Recently, FA has been applied to delineate the contraction-induced assumption of more isotropy 
for tissue architecture in skeletal muscle (Galban, Maderwald et al. 2004; Deux, Malzy et al. 
2008). Mode was proposed in 2006 as an FA-independent metric for anisotropy (Ennis and 
Kindlmann 2006). Mode has been used to detect microstructural anatomy of epidermoid cysts 
and nerve fibers (Jolapara, Kesavadas et al. 2009; Douaud, Jbabdi et al. 2011). However, 
dynamic changes in myocardial architecture for genetically abnormal dystrophic hearts have not 
been investigated with the use of FA or mode. Although FA is more widely used in DTI, we 
propose to include also mode to describe the anisotropy in myocardium, because “No single 
scalar parameter can be constructed which reflects all of the information about anisotropy which 
is contained in the eigenvalues” (Bahn 1999). The 3D information acquired in perfused viable 
mdx hearts should allow delineation of both the locus (regional and intramural) and the cycle 
dependence (diastole vs. systole) of the principle cardiac defects in dystrophin-deficiency and 
whether these defects might be reversible (i.e. functional) consequences of calcium mishandling 
(please refer to Chapter 4) or be nonreversible 
consequences of fibrosis (i.e., remodeling). 
 
Figure 17. Demonstration of anisotropic space spanned 
by FA and Mode. From (Ennis, 2006) 
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3.2. Method: DTI Data Analysis for FA and mode 
Please refer to Chapter 2 for isolated Heart Preparation for DTI and MRI procedure. The 
dataset is the same as acquired in Chapter 2. However, new signal processing method was used 
to extract information from the dataset. All MR images were processed using custom-developed 
software written in Matlab. FA and mode are both calculated from eigenvalues and eigenvectors 
of tensors according to the standard formulas below (Ennis and Kindlmann 2006). 
𝐹𝐴 = √
1
2
 √(𝜆1 − 𝜆𝑚𝑒𝑎𝑛)2 +  (𝜆2 − 𝜆𝑚𝑒𝑎𝑛)2  + (𝜆1 − 𝜆𝑚𝑒𝑎𝑛)2
√𝜆1
2 +  𝜆2
2 + 𝜆3
2
=  √
3
2
 √(𝜆1 − 𝜆2)2 +  (𝜆2 − 𝜆3)2  + (𝜆1 − 𝜆3)2
√𝜆1
2 +  𝜆2
2 + 𝜆3
2
  
, 𝑤ℎ𝑒𝑟𝑒 𝜆1~3 𝑎𝑟𝑒 𝑒𝑖𝑔𝑒𝑛𝑣𝑎𝑙𝑢𝑒𝑠 𝑎𝑛𝑑 𝜆𝑚𝑒𝑎𝑛 𝑖𝑠 𝑡ℎ𝑒 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝜆1~3 
………..eq12 
 
𝑚𝑜𝑑𝑒 = 3 √6 det (
 𝐴𝑎𝑛𝑖𝑠𝑜 
 |𝐴𝑎𝑛𝑖𝑠𝑜 |
) , 𝑤ℎ𝑒𝑟𝑒  𝐴𝑎𝑛𝑖𝑠𝑜 = 𝐴 −
√(𝑒𝑣1 +  𝑒𝑣2 +  𝑒𝑣3)
3
× 𝐼3 
           …………eq13 
3.3. Result  
3.3.1. mdx and WT hearts exhibit lower FA & higher mode 
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In all hearts, systolic FA was ~40% lower than diastolic FA (p < 0.05 for all comparisons, 
Figure 18), indicating that a more isotropic diffusion environment was elicited by cardiac 
contraction (Galban, Maderwald et al. 2004; Deux, Malzy et al. 2008), as expected from fibers 
shortening in the long-axis and expanding in the short axis (i.e., becoming rounder, or less 
oblong). Generally, systolic FA is lower (i.e., spherical instead of a ellipsoidal shape) and mode 
is higher (i.e., oblong instead of a discoid shape, Fig63) than those of diastole (Fig64). In diastole, 
mdx-NC hearts exhibited abnormally low FA and high mode compared to WT, indicating a 
regional unrelaxed myocardial fiber/sheet architecture. After perfusing the mdx heart with low 
[Ca2+] (mdx-LC in Fig64) cardioplegic solution, recovery of diastolic FA and mode to normal 
values were observed.  
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Figure 18. DTI-determined FA and mode in diastole and systole of WT and mdx mouse heart. N 
= 5 for each group. *, p < 0.05. NC, normal calcium. LC, low calcium concentration perfusion. 
See Methods in Chapter 2. 
 
3.4. Discussion – abstract shape information 
The low diastolic FA of mdx hearts, indicating more isotropic fiber/sheets organization 
(Galban, Maderwald et al. 2004; Deux, Malzy et al. 2008), also demonstrates this diastolic 
mechanical defect of mdx hearts. Systolic FA of mdx is lower than that of WT, indicating while 
the mechanical sheet orientation is not affected by the absence of dystrophin in systole, the 
microstructural environment of muscular architecture is affected. This requires further 
investigation. 
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This study shows for the first time that myocardium microstructure of mdx mice exhibits 
abnormal anisotropy that is calcium dependent, loci-dependent,7 and rapidly reversible. Given 
that barium-induced cardiac contraction leads to lower FA and higher mode, the observed lower 
diastolic FA and higher diastolic mode in mdx hearts all reflect that mdx cardiomyocytes are not 
fully relaxed in diastole.  
FA and mode describe the anisotropy of water diffusion in the microscopic environment that 
could represent several factors, including cell shape/size, extra/intracellular volume ratio, 
myofiber dispersion, and myocardial sheet extension, all of which broadly impact 
electromechanical cardiac function. The observation that changing cytosolic [Ca2+] regulates the 
FA and mode in mdx hearts suggests that restoration of cell environment by allowing complete 
relaxation in diastole can be achieved rapidly by transient adjustments in sarcoplasmic calcium 
levels. Accordingly, diastolic dysfunction in mdx mice may be reversible in part with measures 
aimed at restoring normal calcium handling, and is not a permanent pathophysiological feature of 
the disease. Thus, FA and mode are quantitative tissue based metrics to assess microarchitectural 
alterations in cardiomyopathy. 
4.  
  
                                                          
7 Loci-dependent: base is abnormal while apex is normal. 
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Chapter 4: Optical mapping for calcium transients in ex vivo viable 
mdx hearts 
 
 
4.1. Acknowledgements to the contribution of Dr. Efimov’s lab  
After I have found the calcium-dependent regional sheet dysfunction described in last 
Chapter, Samuel Wickline and me proposed a collaboration to Igor Efimov’s lab to test the 
hypothesis of regional abnormal calcium handling in a whole perfused mouse heart. I thank Di 
Lang, Chaoyi Kang, and Igor Efimov for their generous help on optical mapping for studying the 
calcium transients of 16 month old (old) and 3 month old (young) mdx mice. Di found that the 
basal calcium transients are abnormally prolonged only when the heart is stretched in old but not 
young mdx mice, for the first time. Combining Di’s optical mapping findings with my DTI 
findings, we were able to infer that mdx cardiomyopathy is calcium- and loci- dependent (Cheng, 
Lang et al. 2012).   
 
4.2. Why use optical mapping for calcium? 
Ca2+ released by sarcoplasmic reticulum (SR) in cardiac muscle triggers conformation 
change in troponin, allowing the binding between actin and myosin and the following sliding 
action, and results in macroscopic contraction of cardiac muscle. The Ca2+ is released from the 
openings of SR Ca2+ release channel (ryanodine receptor, RyR). The voltage-gated sarcolemmal 
L-type Ca2+ channels (dihydropyridine receptors, DHPRs) locally increase [Ca2+]i and thereby 
activate the RyRs by Ca2+-induced Ca2+ release (CICR). After contraction, sarco/endoplasmic 
reticulum Ca2+-ATPase (SERCA) uptake the cytosol Ca2+ into SR, allowing relaxation (Cheng, 
Lederer et al. 1996). This CICR and Ca2+ recycling triggers every heart cycle. How 
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cardiomyocytes handle calcium is critical to both normal and pathological hearts. Chapter 2 
suggests mdx mice exhibit calcium-dependent sheet dysfunction at base, leading us to 
hypothesize that the base handles calcium differently than the apex. We employed optical 
mapping to investigate calcium handling of mdx mouse hearts for the first time.   
Optical mapping of calcium transients in ex vivo, viable, and intact heart (simply “optical 
mapping” hereafter) uses a camera to capture the time-varying fluorescence signals of calcium-
sensitive dyes. Efimov’s group pioneered the technique two decades ago (Efimov, Huang et al. 
1994). The optical mapping technique is a powerful tool to investigate cardiac calcium transients 
in human, dog and mouse (Fedorov, Chang et al. 2010; Lang, Glukhov et al. 2011; Cheng, Lang 
et al. 2012). However, one needs to either open the chest or prepare an ex vivo Langendorff 
perfused heart to provide access the heart to optical cameras.  
For interested readers, the best publication introducing the setup of optical mapping is on 
The Journal of Visualized Experiments (Lang, Sulkin et al. 2011), which is also from Efimov’s 
lab. It utilizes online video streaming to explain the complex setup efficiently and clearly.  
 http://www.jove.com/video/3275/optical-mapping-action-potentials-calcium-transients-mouse 
 
4.3. Method 
4.3.1.  Isolated heart preparation and calcium dye loading            
Seven Langendorff-perfused hearts (Lang, Glukhov et al. 2011) from 16 month old mice were 
separated into two groups (mdx, N=4; and WT(C57BL/6), N=3). In brief, after anesthesia and 
heart excision, a short section of aorta was attached to a 21-gauge cannula. After cannulation, 
hearts were superfused and retrogradely perfused with oxygenated (95% O2, 5% CO2) constant-
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temperature (37±1oC), modified Tyrode solution (in mmol/L: NaCl 128.2, KCl 4.7, NaH2PO4 
1.19, MgCl2 1.05, CaCl2 1.3, NaHCO3 20.0, and glucose 11.1 (pH=7.3)) that was passed through 
a 5 μm filter (Millipore, Billerica, USA). Perfusion was performed using a peristaltic pump (Peri-
Star, WPI, Sarasota, USA) under a constant aortic pressure of 60 – 80 mm Hg. 
The isolated heart was pinned at the edge of ventricular apex to the Sylgard bottom of the 
chamber to prevent stream-induced movement. A small silicon drain tube was inserted into the 
left ventricle through the pulmonary vein, left atria, and tricuspid valve to prevent solution 
congestion and subsequent ischemia. A piece of small black tape was used to cover the atria to 
avoid fluorescence scattering from the atria. The excitation-contraction uncoupler Blebbistatin8 
(10 µM, Tocris Bioscience, USA) was used to prevent motion artifact on the action potential 
duration estimation. The heart was then stained with a calcium indicator (Rhod-2 AM, Invitrogen, 
Carlsbad, CA, 30μL of 1 mg/mL dimethyl sulfoxide, 1:1 mixed with Fluronic F127, Invitrogen, 
Carlsbad, CA in Tyrode’s solution), for 5-7 minutes. 
 
4.3.2. Optical imaging system 
The excitation light was generated by a halogen lamp (Newport Oriel Instruments, 
Stratford, CT; SciMedia, Costa Mesa, CA) and passed through a heat filter, shutter, and 
excitation band-pass filter (520 ± 45 nm). A flexible light guide directed the band-pass filtered 
light onto the preparation. The optical mapping apparatus comprised an MiCAM Ultima-L 
CMOS camera (SciMedia, Costa Mesa, CA) with high spatial (100x100 pixels, 230±20 μm per 
pixel) and temporal (1,000-3,000 frames/sec) resolution. A band-pass filter (59015 nm, 
Thorlabs, Newton, NJ) was fixed in front of the calcium-imaging camera.  
                                                          
8 Blebbistatin will stop the muscle contraction, allowing motion free calcium transients recording. 
49 
 
 
4.3.3. Optical mapping protocols 
After isolation and cannulation, motion suppression, and dye staining, prepared hearts 
were equilibrated for 5-10 min before imaging. The optical mapping signals were recorded 
sequentially under unloaded and stretched conditions. The unloaded condition was achieved by a 
pressure releasing silicon tube inserted into the LV chamber of the Langendorff heart preparation 
mentioned above. The stretched condition was achieved by inflating the LV chamber with 
Tyrode’s solution to 80 mmHg pressure through the silicon tube inserted into the left ventricle. 
The perfusion pressure was increased from 60 to 100 mmHg to maintain the direction of the 
retrograde perfusion and the viability of the perfused heart. A steady-state restitution (S1-
S1)(Lang, Glukhov et al. 2011) pacing protocol was applied under both conditions. 
 
4.3.4. Optical mapping data processing 
A custom-designed Matlab program was used to analyze the optical signals, which were 
filtered with a low-pass Butterworth filter at 256 Hz. Regional calcium dynamics were quantified 
in WT and mdx mouse ventricles (base vs. apex) under both unloaded and stretched conditions. 
Hand-drawn regions of interest were used to define basal (upper 1/3 area of left ventricle) vs. 
apical regions (lower 1/3 area of left ventricle). The calcium decay signal is not monoexponential 
and only the latter half of the decay signal could be fitted exponentially to derive the decay 
constant. Thus, both T50 and decay constant (Figure 19 A) are commonly used to characterize 
calcium relaxation kinetics (Giordano, He et al. 1997; Vassalle and Lin 2004; Zhu, Altschafl et 
al. 2005; Mukherjee, Apple et al. 2006; Taylor, Al-Saadi et al. 2006; Williams and Allen 2007; 
Sahoo and Kim do 2008; Sahoo, Kim et al. 2009; Chase and Orchard 2011; Mellor, Wendt et al. 
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2012). Specifically, Ca relaxation time from the calcium transient peak value to 50% relaxation 
(T50) was calculated to define the early calcium reuptake phase; and Ca decay constant was 
calculated using an exponential curve fitting program from the 50% calcium peak value to ful 
relaxation. Taken together, the T50 and the decay constant characterize the whole process of Ca 
reuptake-dependent relaxation. 
 
 
4.4. Optical Mapping Results 
4.4.1. Optical imaging reveals longer calcium decay time (T50) in 16 month old 
mdx mice 
Under unloaded conditions, T50 was comparable between mdx and WT hearts. However, 
ventricular stretch elicited an approximately 25% increase in T50 (from 40  2 ms to 51  3 ms, 
p < 0.05, Figure 19) and approximately 50% increase of decay constant (from 25  1 ms to 37  
1 ms, p < 0.05) at the base of mdx hearts, confirming abnormal calcium uptake in this region. 
Ventricular stretch, however, did not affect the T50 nor decay constant at the apex of mdx hearts, 
nor in the entire left ventricle of WT hearts, indicating a heterogeneous regional dependency on 
the development of abnormal calcium handling in mdx. 
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Figure 19. Calcium relaxation for mdx and WT. A, representative calcium transients at the base 
of a WT (blue line) and a mdx (red line) hearts. Signals were averaged from adjacent 25 CCD 
elements. Definitions of T50 and  are illustrated. B & C, representative T50 and decay constant 
maps in mdx and a WT hearts under unloaded versus loaded (stretched) condition. D & E, under 
unloaded conditions, both T50 and decay constant were comparable between mdx and WT hearts. 
Ventricular stretch caused regional increases of T50 and decay constant at the base of mdx hearts. 
However, WT hearts exhibit similar T50 and decay constant. *, p < 0.05; **, p < 0.01. 
 
4.4.2. 3 month old mdx mice exhibit normal calcium transients 
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Surprisingly, despite the fact that mdx mice lack dystrophin since embryo, the prolonged 
calcium transient abnormality did not exist in young mice (3 month old) whether stretched or not, 
while abnormal calcium transient exist at the base of old mdx mice (16 month old), only when 
stretched. Representative figures are shown in Figure 20. 
 
Figure 20. Calcium transient duration at 80% relaxation is only abnormal (red) in 16 month old 
mdx when stretched; but is normal (blue) when young or unstretched. T50 and decay constant 
exhibit the same pattern (not shown). 
 
4.5. Discussion of regional abnormality at base 
The prior recognition of stretch induced calcium mishandling in isolated mdx 
cardiomyocytes informs the present work (Williams and Allen 2007; Fanchaouy, Polakova et al. 
2009). Specifically, mechanical stretch increases opening chance of stretch-activated channels 
(SAC) (Williams and Allen 2007) and induces transient membrane microruptures in mdx 
cardiomyocytes (Townsend, Blankinship et al. 2007; Townsend, Yasuda et al. 2007). The 
resultant leakage of extracellular calcium into the cytosol then compromises calcium clearance 
during relaxation and renders mdx cardiomyocytes vulnerable to stretch induced injury (Sapp, 
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Bobet et al. 1996). In this study of intact perfused hearts, we employed a stretch protocol to 
mimic cardiomyocyte activity under moderate strain regimes by inflating LV pressure to 80 
mmHg, which is similar to that used for investigating fibrillation by several groups (Nazir and 
Lab 1996; Bode, Katchman et al. 2000; Zarse, Stellbrink et al. 2001; Eijsbouts, Majidi et al. 
2003; Huang, Tai et al. 2003). Under the stretched condition, mdx hearts exhibited regional 
deficiency in calcium uptake, as evidenced by the prolonged T50 and decay time constant, at the 
base where the sheet functional defect was observed. Thus, our results illustrate a regional 
correspondence between abnormal diastolic sheet mechanics and disturbed calcium kinetics. 
Because sheet function is a key determinant of ventricular wall strain (Costa, Takayama et al. 1999; Usyk, 
Mazhari et al. 2000), and calcium mishandling in mdx cardiomyocytes is associated with cellular injury 
(Lynch 2004; Williams and Allen 2007; Prosser, Ward et al. 2011), the observed stretch-induced regional 
calcium mishandling in mdx hearts may be responsible in part for the local progression of diastolic sheet 
dysfunction. 
 
4.6. Discussion of the perfusion condition in DTI and optic mapping 
Results in Chapter 2 and 3 agree that abnormalities exist at the base of mdx hearts. However, 
Chapter 4 suggests the calcium transient abnormalities only when the left ventricle (LV) is 
stretched by 80 mmHg pressure. Why do I see abnormalities at base in Chapter 2 without 
stretching? Here is a possible explanation: In the DTI study, the LV was not vented, while in the 
optical mapping study, the LV was vented with a tube inserted in the LV through left atrium. I 
did not use the venting tube in DTI study, in order to avoid susceptibility artifacts and sliding 
motion-artifact of the tube. A venting tube in LV creates two surfaces of water/non-water 
materials and usually brings microbubbles into the LV. The surfaces and microbubbles both 
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generate unwanted susceptibility artifacts of MRI (Sakurai, Fujita et al. 1992). Furthermore, the 
tube tends to slide by few millimeter during the 1.5 hr long DTI study and generate motion 
artifacts. However, in optical mapping, all the signals were collected from the surface of a heart. 
Therefore, a tube in the LV does not affect optical imaging but does prevent the congestion of 
the perfusate and metabolism acidification in the LV, making a venting tube desirable for optical 
mapping study. In DTI, the metabolism acidification is less worrisome because the heart was 
arrested in diastole with the cardioplegic solution under 18 Celsius temperature which minimize 
the metabolism activity. In conclusion, in DTI study, all the hearts are not vented, therefore, the 
LV might be stretched by the perfusion pressure delivered through aorta valve incompetence or 
the Thebesian veins, during the 30~45 min long imaging setup time. In the future, a thin pressure 
transducer can be used to measure the pressure in the unvented LV for prolonged DTI 
acquisition to clarify this issue.   
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5.  
Chapter 5: Autophagy and Beneficial Effects of Rapamycin-nanoparticle 
 
 
5.1. Acknowledgements 
Experiment were designed by Bibee Kristine, Jon Marsh, Samuel Wickline and me. Richard 
Killing and I performed strength measurements. Sharron Yang and I performed autophagy 
nanoparticle treatments. Huiying Zhang and I performed histology of myocardium. 
Echocardiography ejection fraction were performed and processed by Dr. Jon Marsh. Western 
blots were performed by Dr. Kristine Bibee and Dr. James Ching.  
 
5.2. Abstract 
Current supportive therapy for DMD patients with corticosteroids results in a modest 
increase in strength as a consequence of a general reduction in inflammation, albeit with 
potential untoward long-term side effects and ultimate failure of the agent to maintain strength. 
Here, we demonstrate that rescuing defective autophagy in mdx mice, a model of DMD, with the 
use of rapamycin-loaded nanoparticles (RNP) induces a reproducible increase in both skeletal 
muscle strength and cardiac ejection fraction that is not achievable with conventional oral 
rapamycin delivery. Rapamycin induces autophagy, or “self-eating”, which is a cellular process 
responsible for recycling metabolites and eliminating toxic byproducts. The resulted increase in 
physical performance occurs in both young and adult mice, and surprisingly even in aged wild-
type mice. RNP treatment of old mdx mice increases autophagic activity with rapid beneficial 
consequences for improved LV function after only eight doses. 
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5.3. Introduction 
As discussed earlier, DMD now is treated symptomatically with corticosteroids, resulting in a 
modest increase in strength albeit with expected and unavoidable side effects (Balaban, 
Matthews et al. 2005; Markham, Spicer et al. 2005; Moxley, Ashwal et al. 2005; Biggar, Harris 
et al. 2006). However, the cardiac phenotype has proven difficult to modify, and pursuit of 
combination therapies that might be steroid sparing remains an active area of research (van 
Deutekom, Janson et al. 2007; Kinali, Arechavala-Gomeza et al. 2009; Cirak, Arechavala-
Gomeza et al. 2011; Goemans, Tulinius et al. 2011). 
New pharmaceutical strategies other than steroid are desirable. A recent promising treatment 
target is the autophagy pathway, which is a cellular process responsible for recycling reusable 
products of metabolism and/or efficient elimination of toxic byproducts (Kundu and Thompson 
2008).  Indeed, rapamycin, a known inducer of autophagy, was reported by Eghtesad et al. 
(Eghtesad, Jhunjhunwala et al. 2011) in 6-week-old mdx mice to improve diaphragm muscle 
histopathology. Protein restriction has been shown to activate autophagy in 16-week-old mdx 
leading to enhanced grip strength (De Palma, Morisi et al. 2012).  Recent work by Pauly et al. 
has demonstrated that autophagy induction in the diaphragm of 6-week-old mdx animals by daily 
intraperitoneal injections of an AMP-activated protein kinase agonist also promotes clearance of 
defective mitochondria and improves diaphragm strength (Pauly, Daussin et al. 2012).  However, 
the potential benefits of enhancing autophagy in multiple muscle groups with the use of 
clinically practicable therapeutic agents that might elicit rapid and repeatable responses in both 
global physical performance and cardiac functionality in vivo over a broad range of ages (e.g., 
≥16 months) have not been examined. 
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Rapamycin, an immune-suppressing macrolide typically used to prevent organ transplant 
rejection and as an anti-inflammatory agent to prevent angioplasty restenosis (Vilquin, Asselin et 
al. 1995; Thomson, Turnquist et al. 2009; Adelman), is known to induce autophagy, thereby 
inciting a cell survival program that enables useful recycling of amino acids via non-specific 
degradation of long-lived proteins and dysfunctional organelles (Shigemitsu, Tsujishita et al. 
1999).  By binding to the mammalian target of rapamycin complex 1 (mTORC1), rapamycin 
blocks proliferative signaling (Wullschleger, Loewith et al. 2006). Paradoxically, blocking 
mTORC1 with rapamycin might be expected to exert deleterious effects on protein synthesis, 
muscle fiber regeneration, and cell growth in mdx mice, all of which might be expected to 
maintain strength.  However, if autophagy is fundamentally defective in DMD/mdx and can be 
shown to reverse weakness and cardiac dysfunction, and if a method for effective delivery of 
clinically approved doses of rapamycin to muscle tissues that might enhance autophagy and 
improve endurance can be designed, then a compelling mechanistic link between disturbed 
autophagy and progressive deterioration of global physical strength and contractile performance 
in vivo would be suggested. 
Nanoparticle therapeutics for treating cancer and other pathologies are now undergoing 
clinical trials in multiple drug combinations (Etheridge, Campbell et al. 2013), but heretofore 
have not been evaluated in neuromuscular diseases.  The potential advantage conferred by such 
agents is their high local accumulation at sites of disease in concert with the use of lower serum 
levels of free drug that would limit unwanted off targeted side effects, as has been shown for 
Doxil™ and Abraxane™ in cancer for example.  Accordingly, we compared both an oral 
preparation of rapamycin and an intravenous nanoparticle-based formulation of rapamycin (RNP) 
for ability to improve a clinically significant global performance factor related to endurance and 
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grip strength, with the use of validated methods that are translationally relevant and highly 
correlated with mortality in the mdx model (Keeling, Golumbek et al. 2007).  Furthermore, we 
measured autophagic responses to rapamycin nanoparticles in skeletal muscle tissues for 
correlation with grip strength metrics (designed and performed by Jon Marsh and Kristine Bibee). 
Finally, we delineated the effects of these agents on cardiac function in aged mdx and wild-type 
mice. 
 
5.4. Methods 
5.4.1. Reagents 
All chemicals were purchased from Sigma-Aldrich, Inc. (St. Louis, MO, USA) unless 
otherwise specified. 
5.4.2. Nanoparticle formulation 
The perfluorocarbon nanoparticle emulsions without or with rapamycin (at a 
concentration of 0.275 mol%) were prepared as previously described (Cyrus, Zhang et al. 2008).  
In general the sizes of the PFC NP range between ~160-240 nm (Wickline, Neubauer et al. 2006; 
Wickline, Mason et al. 2010). As an example, batch MS1-92b exhibited a diameter of 184.7 nm, 
polydispersity 0.120, and zeta potential -15.31 mV. We note from prior experience that drug 
loading has little effect on the size but may affect zeta potential depending on the exact 
composition and charge of the loaded moiety (Soman, Lanza et al. 2008; Soman, Baldwin et al. 
2009). An additional, dual-fluorophore emulsion was formulated to verify delivery of both 
nanoparticles and rapamycin to skeletal muscle. The emulsion lipid moiety incorporated 
rhodamine B (Avanti Polar Lipids, Alabaster, AL, USA), and the rapamycin was conjugated 
with a near-infrared (IR) fluorescent dye (Cy7.5, Lumiprobe Corporation, Hallandale Beach, FL) 
before formulation into the nanoparticles. Perfluorocarbon nanoparticles are exceedingly stable 
in blood as they were originally developed as a blood substitute (Flaim 1994). The stability of 
rapamycin incorporated into nanoparticles has been reported previously (Cyrus, Zhang et al. 
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2008). Drug release kinetics against an infinite sink of releasing medium in vitro verified 
retention of 97% of nanoparticle rapamycin over three days. 
5.4.3. Animal studies 
Strength studies:  Male mdx mice (strain C57BL/10ScSn-Dmdmdx/J) and age-matched 
controls (strain C57BL/10SnJ) were purchased from The Jackson Laboratory (Bar Harbor, ME, 
USA).  All mice were housed in the same animal facility and cared for under approval by 
Washington University’s animal study committee. Starting at age 14 weeks, mice were injected 
twice weekly for four weeks with plain nanoparticles (n=18 for mdx, n=4 for control) or 
nanoparticles loaded with rapamycin (n=16 for mdx, n=5 for wild-type).  Dosage was 1 mL 
emulsion/kg body mass, injected via lateral tail vein resulting in approximately 0.002 mg 
rapamycin per animal per treatment.  An additional set of mdx (n=8) mice was housed in an 
AAALAC-approved facility until they were 17 months of age, at which point they received 4 
weeks of RNP treatment as described above.  
Separate groups were utilized for oral rapamycin therapy.  For these animals, rapamycin was 
solubilized in grain alcohol and was delivered in a mixture of dextrose and water twice weekly 
for four weeks via micropipette gavage, typically 40–50 µL per mouse. There were three 
treatment groups: mdx mice given rapamycin (n=6); control mice given rapamycin (n=6); and 
mdx mice given placebo (n=6).   
Treatment effectiveness was determined by measuring forelimb grip strength within one 
week before beginning each treatment regimen, and subsequently within one week after 
treatment completion.  Strength testing was performed in blinded fashion by an experienced 
technician as previously described by our group (Keeling, Golumbek et al. 2007) and by others 
who have used this standardized test of physical fitness and endurance.  Strength testing was 
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performed using a grip meter attached to a force transducer (E-DF 002 Digital Force Gauge, 
Chatillon Force Measurement Systems, Largo, FL, USA).   The tests relied on the animal’s 
instinct to grab hold as it was pulled backward.  Each mouse was grasped by the tail and 
encouraged to grab a trapeze bar attached to the force transducer using its forelimbs.  The mouse 
was then pulled away and the peak force was recorded on a digital display.  This procedure was 
repeated five times in a row for each animal.  The three highest readings were averaged and 
normalized by the animal’s weight to give the strength score.  
Rapamycin nanoparticle drug holiday studies: To determine if the effects of RNP on grip 
strength were reproducible in individual animals, a cohort (n=7 for mdx/no drug, n=8 for 
mdx/rapamycin, n=4 for wild-type/no drug, and n=5 for wild-type/rapamycin) of the originally 
treated 14-week-old mice was maintained off drug therapy over the span of 18-34 weeks of age 
to allow washout of the RNP effect.  The same one month RNP treatment and grip strength 
testing regimen was then repeated for 1 month starting at age 34 wks. 
Cardiac studies: A cohort of 17-month old mdx mice received either RNP (n=9) i.v. via eight 
tail vein injections (1.5 mL/kg/dose), 2x/week over four weeks to deliver the same cumulative 
amount of rapamycin as for the other studies above or no treatment (n=7).  Wild-type mice of the 
same age were used as controls (n=6 for RNP, n=8 for no treatment).  The mice were lightly 
anesthetized for cardiac ultrasonography with isoflurane and placed supine for examination with 
a 16 MHz array (Spark, Ardent Sound, Inc., Mesa, AZ, USA). Prior to imaging, the thorax of 
each animal was shaved and depilated. Animal body temperature was maintained with a heated 
water blanket and thermistor-controlled heating lamp. Heated ultrasound coupling gel was 
liberally applied to the shaved area. Waveforms were sampled at the system's clock frequency 
(66.67 MHz) using a 12-bit digitizer (GaGe Compuscope 12400, DynamicSignals LLC, 
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Lockport, IL, USA).  Two hundred frames of cardiac data were acquired for each view at a frame 
rate of 152 Hz, with each frame consisting of 128 A-lines (2048 sampled points/line).  Each loop 
thus consisted of between 8 and 12 heart cycles.  Radiofrequency (RF) data were converted to 
scaled image data using custom plugins written for the open-source image processing software 
ImageJ (Rasband, W.S., U. S. National Institutes of Health, Bethesda, MD, USA, 
http://imagej.nih.gov/ij/, 1997-2013).  Backscattered ultrasound energy was mapped to grayscale 
by taking the log of the sum of the squares of the digitized voltage values in a center-weighted 
moving window.  The resulting image loops were scaled to a resolution of 0.05 mm/pixel.  Left 
ventricular ejection fraction (LVEF) was computed using ImageJ by manually tracing the 
ventricular endocardium border at systole and diastole in the short-axis (SAX) view for each beat 
and by recording the area region of interest (ROI).  Ventricular length was computed from the 
long-axis (LAX) view by determining the length of a line manually drawn from the apex 
endocardium to the aortic valve plane.  Left ventricular volume at systole (or diastole) was 
estimated by computing the volume of an ellipsoid having a circular cross-section equal to the 
mean systolic (or diastolic) ROI area and length equal to the mean systolic (or diastolic) 
measured ventricular length.  LVEF was then computed as the ratio of the difference in volume 
of this ellipsoid between diastole and systole, and the diastolic volume.  
 
5.4.4. Histology 
Fibrosis imaging was performed in the diaphragm by analyzing trichrome stained (Masson), 
formalin-fixed sections (8-µm thickness) with a stain kit (HT-15-1KT, Sigma-Aldrich) and in the 
heart with picrosirius red stains per standard protocol (Dolber and Spach 1987).  Color light 
microscope images of collagen were acquired from five randomly selected fields for each 
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diaphragm section at 200X with an Olympus BX61 microscope and F-View camera (Olympus 
America Inc., 3500 Corporate Parkway, Center Valley, PA, USA).  Similar assessments were 
performed for basal heart sections from 5 treated and 5 untreated mdx. Custom software (written 
as a plugin for ImageJ) was used to quantify the area of each image associated with collagen-
labeled pixels relative to the area of each image associated with tissue of any type.  
For fluorescence histologic imaging, 14-week old mdx mice were given intravenous 
injections (1 mL/kg) of dual-labeled fluorescent nanoparticles and sacrificed 4 hours post-
injection following systemic saline perfusion to wash out any residual circulating nanoparticles. 
Nanoparticle and/or rapamycin tissue distribution was demonstrated in the biceps, diaphragm, 
gluteus, and myocardium of mice injected with fluorophore-loaded emulsions in excised and 
frozen (OCT medium: Tissue-Tek, Sakura Finetek, Torrance, CA, USA) or paraffin-embedded 
tissues.  Sectioning (8-µm) was performed on 10 consecutive slides from each tissue sample (a 
total of 60 slides were prepared), and random sections were chosen by a blinded observer for 
fluorescence microscopy. Adjacent slides were saved for H&E.  Multiple images were acquired 
from each section with an Olympus BX51 fluorescence microscope image system, using an 
Infinity3 camera (Lumenera Corporation, Ottawa, Ontario, Canada) for optical image recording 
and digitization, and F-View II B&W CCD camera for fluorescent images. 
 
Tissue nanoparticle biodistribution 
19F perfluorocarbon-core nanoparticles were administered to 14 mdx mice (18 weeks old) 
by tail vein injection; and tissue and organ harvesting conducted at either 2, 12, or 24 hours. 
Tissues harvested for measurement of nanoparticle concentrations were acquired after in situ 
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perfusion fixation of the mouse that was initiated by cardiac puncture and flow-through of buffer 
solution until venous effluent was clear (~10 min).  This washout procedure ensured that blood 
contamination was not a factor in the estimation of tissue nanoparticle content.  We also note that 
the tissue distributions and clearances for similar particles are not affected by drug loading and 
have been reported before for mice and rabbits (Hu 2007; Soman, Lanza et al. 2008; Soman, 
Baldwin et al. 2009). The specimens were blotted dry, weighed, fixed in formalin, and then 
subjected to fluorine spectroscopy with the use of an 11.7T Varian MRI/MRS scanner and a 
custom-built single-turn solenoid coil.  19F spectra signal from each specimen and from a 
standard of perfluoro-15-crown-5 ether were obtained via non-localized 90-FID spectroscopy 
(2.5-s pulse repetition time TR, and 128, 256, or 512 signal averages NT).  The unique and 
quantitative fluorine signature was expressed as total tissue fluorine content per gram. This 
methodology fortunately avoids the necessity for extraction of the target compound 
(perfluorocarbon in this case) with its attendant inefficiencies, since the total amount of 19F 
signal in the entire unprocessed tissue can be registered nondestructively.  Because there is a 
direct and linear relationship between the 19F signal and the nanoparticle concentration, the 
analytical method yields essentially the nanoparticle concentration per unit tissue mass 
(Morawski, Winter et al. 2004). 
 
Creatine Kinase 
Blood was obtained by left ventricular cardiocentesis, and serum extracted by 
centrifugation.  Serum creatine kinase (CK) levels were measured spectrophotometrically with a 
Vitros DT60 dry reagent chemistry analyzer (OrthoClinical Diagnostics, Raritan, NJ, USA). 
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Autophagy and autophagic flux measurements 
Muscle tissues were extracted from the mdx mice and homogenized in 0.5 mL of RIPA 
buffer with 1-mM PMSF, Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN, USA), 
and Phosphatase Inhibitor Cocktail (Roche) using a glass grinding tube. The tissue homogenates 
were centrifuged at 10,000xg for 10 min at 4°C and the supernatant was stored at -80°C.   
Proteins in tissue homogenates were resolved on a NuPAGE Novex 4-12% Bis-Tris Gel 
(Invitrogen, Carlsbad, CA, USA), transferred to 0.2 µM nitrocellulose, blocked in 5.0% 
milk/TBS-T and incubated with the following primary antibodies: rabbit anti-pS6 (1:1000, Cell 
Signaling 4857, Boston, MA, USA), rabbit anti-S6 (1:1000, Cell Signaling 2217), rabbit anti-
LC3B (1:2000, Sigma-Aldrich), rabbit anti-Beclin1 (1:1000, Cell Signaling), goat anti-actin 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Corresponding secondary antibodies 
were used at 1:5000.  Protein bands were visualized using either ECL Western Blotting Substrate 
(Pierce 32106, Rockford, IL, USA) or Super Signal West Femto Maximum Sensitivity Substrate 
(Pierce 34095). Western blot image was used to calculate relative protein expression using 
densitometry with ImageJ. Values were normalized to myosin loading control and reported as 
fold change compared to the control, non-treated sample. 
To illustrate how this approach might apply to actual primary human cells and be 
potentially generalizable, tumor cells (HIM3 line from the Washington University HAMLET 
Core) were derived from a biopsy specimen that was procured from a triple negative primary 
breast tumor and were passaged through immunodeficient animals in a method described 
previously (Ding, Ellis et al.).  Cells were maintained in McCoy’s 5A media (Invitrogen, 
Carlsbad, CA) supplemented with 10% FBS (Sigma, St. Louis, MO) and penicillin/streptomycin 
(Invitrogen, Carlsbad, CA) in a 37o C humidified tissue culture incubator with 5% carbon dioxide.  
Lentivirus containing the LC3-GFP fusion was obtained from C. Weihl (Washington University, 
St. Louis, MO).  The cells were transfected using a standard spinfection method with protamine 
sulfate.  After recovery, the cells were sorted on a BD Aria II High Speed Cell Sorter three times 
with one-week recovery periods between each sort.  The stable cell lines were then treated for 24 
hours with DMSO (vehicle for rapamycin), rapamycin (100nM), nanoparticles (3.09x1010 
particles/mL), or rapamycin-nanoparticles (3.09x1010 particles/mL = 100nM rapamycin).  After 
treatment, the cells were washed, fixed with paraformadehyde and imaged with a Zeiss LSM510 
65 
 
microscope.  GFP-positive puncta were counted by a blinded observer. Other treated cells were 
prepared for transmission electron microscopy per standard protocols 
For in vivo autophagic flux assessment, we utilized a recently developed autophagic flux 
assay that measures turnover of LC3B-II in mouse skeletal muscle by comparing mice treated 
with and without a potent blocker of autophagic protein degradation (colchicine) (Ju, Miller et 
al.). Colchicine was administered over 48 hours in two doses (0.4 mg/kg) delivered 
intraperitoneally, followed by diaphragm or heart tissue collection.  Tissue homogenates were 
probed as above. 
A separate set of experiments using oral prednisolone as the active agent was conducted 
to delineate potential mechanistic similarities between RNP and steroids with respect to their 
effects on autophagy for an agent that is known to improve strength experimentally and in 
patients.  Four mdx mice were treated with oral prednisolone and four control mdx were treated 
with vehicle for 42 weeks (starting at age 4 weeks), after which muscle tissues [tibialis anterior 
(TA)] were extracted for autophagy measurements as above. 
 
Statistics 
Statistics were generated as noted below for selected ANOVA, t-test, and groupwise 
comparison procedures using SAS software (SAS Institute, Cary, NC, USA) and the open-source 
statistical package R (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-
project.org). 
 
5.5. Results 
 
5.5.1. Rapid enhancement of global physical performance with RNP 
None of the fourteen-week-old mdx and wild-type mice treated with nanoparticles 
demonstrated apparent adverse effects from the treatment at any time point and all animals 
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completed the study.  Figure 21a shows that grip strength increased significantly when RNP 
were employed as therapy (30% absolute increase in mean strength of group). Unexpectedly, 
when nanoparticles (NP) alone were employed as therapy, grip strength exhibited a trend toward 
a modest strength increase (Figure 21a) of 8%.    
To determine whether the grip strength improvement was due to the drug alone, animals 
were treated with oral rapamycin administered at 10x the equivalent nanoparticle i.v. dose to 
account for an expected 10% oral absorption rate (Napoli, Wang et al. 1997; Crowe, Bruelisauer 
et al. 1999; Stepkowski 2003; O'Reilly, McSheehy et al.).  As shown in Figure 21a, the oral 
rapamycin did not improve grip strength.  Age-matched wild-type mice exhibited no significant 
increase in grip strength when treated with rapamycin-loaded nanoparticles or oral rapamycin 
(Figure 21b).  
Figure 21c shows that over this washout interval, strength declined as anticipated.  After the 
repeat dosing of i.v. RNP, grip strength once again improved in the older mdx animals (p=0.008, 
linear contrast model). No significant trend was observed in wild-type mice (Figure 21d).  
Interestingly, RNP treatment of a cohort of 17-month-old mdx (n=8) mice treated for a month in 
similar fashion revealed a more muted effect on strength (Figure 22a: p = 0.201, two-tailed 
paired t-test). 
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Figure 21.  Rapamycin-loaded nanoparticle treatment improves strength in mdx mice.   
a) Four weeks of treatment with rapamycin-loaded nanoparticles (RNP) delivered intravenously 
significantly increased mean weight-normalized grip strength in 14-week old mdx animals (n=16) 
vs. groups given plain nanoparticles (NP) IV (n=18), equivalent oral doses of rapamycin (n=6), 
or oral placebo (n=6) (p=0.012, p=0.027, and p=0.016, respectively, using Fisher’s protected 
least significant difference at 5% significance level).  b) No significant difference in mean 
strength was observed for age-matched wild-type mice given either NP (n=4) or RNP 
intravenously (n=5) or oral rapamycin (n=6).  c) The increase in weight-normalized strength in a 
subset of mdx mice (n=8) treated with IV RNP occurred in both young (14-18 wk) and old (34-
38 wk) animals (p=0.008 using a linear contrast model comparing pre- to post-treatment 
differences at a 5% significance level). Absolute values of the mean change in strength between 
time points are shown in columns below trend data.  d) Wild-type mice (n=5) given a similar 
longitudinal treatment and drug-holiday exhibited no significant difference between pre- and 
post-treatment strength (p=0.598).  All bar graphs show mean values +/- s.e.m.  
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Figure 22. Aged mdx mice show muted responses in grip strength after treatment with RNP, but 
marked improvement in cardiac function commensurate with wild-type animals 
a) Four weeks of treatment of 17-month-old mdx (n=8) yielded no significant increase in grip 
strength (p=0.201, two-tailed paired t-test). b) LVEF in wild-type mice is greater than mdx 
before treatment (p=0.016), as expected. c) Cardiac function significantly improved after RNP 
therapy, irrespective of animal type (16% difference for mdx and 9% difference for WT; 
p=0.024).   
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5.5.2. Rapid enhancement of cardiac performance with RPN in aged mice 
 In the cohort of 17 month-old mdx and wild-type mice, one month of biweekly RNP versus 
no treatment yielded two compelling findings: 1) LVEF in mdx was significantly lower than that 
of wild-type mice before treatment (p=0.016) as expected (Figure 22b); and 2) LV ejection 
fraction for RNP treated mice was 57 ± 2.9 %, and approximately 16% higher than that of none-
treated mdx mice (49 ± 2.5 %; p=0.024).   
    
5.5.3. Nanoparticle tissue distribution 
Results of fluorescence microscopy of fluorophore-labeled rapamycin and fluorophore-
labeled lipids contained in the outer nanoparticle shell are shown in Figure 23. It is clear that the 
particles penetrate heart tissue to deliver rapamycin locally (Figure 23). The labeled rapamycin 
appears to achieve an even greater penetration into tissues than do the nanoparticles, arguing for 
some degree of local rapamycin release and more complete passive diffusion.  We note that the 
use of the near-IR fluorophore avoids the problem of background autofluorescence, thereby 
permitting confident assessment of the more diffuse penetration of rapamycin into muscle tissues 
beyond the loci of nanoparticle deposition. The observation of diffuse rapamycin penetration into 
tissues beyond the nanoparticle carriers (Figure 23) was further supported by analyzing both 
blank slides and unstained muscle tissue specimens that were microscopically digitized at the 
same settings to rule out background signals of any type that might have overlapped with the 
rapamycin signal, and none were observed (data not shown). 
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Figure 23.  Nanoparticles and rapamycin 
are delivered to cardiac muscle in mdx 
animals. 
Nanoparticle lipid (rhodamine, displayed as 
blue) and rapamycin (Cy7.5, labeled as red) 
are colocalized in mdx cardiac tissue. 
 
 
 
 
 
 
 
 
 
 
5.5.4. Effects on skeletal and cardiac mTOR and autophagic processes 
To further demonstrate that the drug reaches muscle tissue and then acts on a known target, 
lysates from the muscle were probed for phosphorylated S6.  S6 is downstream of mTORC1, so 
that blocking mTORC1 with rapamycin should cause a decrease in pS6 levels.  Indeed, in 
diaphragm, triceps, biceps, and gluteus, S6 levels were decreased in mdx animals treated with 
rapamycin-loaded nanoparticles when compared to mice treated with nanoparticles alone (Figure 
24a).  Interestingly, the nanoparticles themselves caused a modest increase in pS6 levels when 
compared with saline treated animals.  Thus, the particle itself may induce signaling through 
mTORC1, but adding rapamycin to the particle then decreases the level of signaling, yet does not 
cause a return to baseline levels.  
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Our data confirm that the mdx mouse harbors a defect in autophagy in muscle tissues, as 
there is an increase in p62 protein (Figure 24b) with no difference in p62 transcription (Figure 
24c).  This expression pattern suggests that p62 is not being consumed in the process of 
autophagy in the mdx animal as it is in the wild-type animals.  Further, BNIP3, a protein that is 
known to trigger autophagy, is found at lower levels in mdx animals when compared to wild-type 
(Figure 24b, c). Additional in vivo confirmation of the effects of rapamycin nanoparticles on 
autophagy revealed that basal autophagic flux was diminished in mdx mouse heart as 
demonstrated by comparing the change in LC3II protein levels with and without colchicine 
treatment (Figure 24d).  
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Figure 24. mdx animals exhibit a defect in autophagy that is restored by nanoparticle treatment. 
a) RNP cause a decrease in S6 levels in mdx animals when compared to NP treatment.  However, 
compared to saline treatment, the NP increased S6 phosphorylation in all muscle groups tested, a 
trend not observed in the muscles from wild-type animals. b) Proteins were extracted from mdx 
and age-matched control animal muscle.  Western blot analysis for p62 (n=5 per group) and 
BNIP3 (n=3 per group) reveal a defect in autophagy as mdx animals exhibited higher levels of 
p62 and lower BNIP3 when compared to wild-type (Student’s t-test at 5% significance level).  
Myosin was used as the loading control.  c) RNA was isolated from the tibialis anterior muscle 
of age matched mdx (n=5) and control mice (n=3).  QPCR was performed and normalized to 
GAPDH.  Graph demonstrates fold change in the following transcripts vs. control:  there was no 
change in p62, BNIP3 or beclin.  Beta 2 microglobin is increased as expected, because it is part 
of MHCI, which is known to be upregulated in mdx muscle.  Actin levels (normal) serve as an 
internal control.  d) Representative Western blots demonstrate that both nanoparticle (NP) and 
rapamycin-loaded nanoparticles (RNP) increase the levels of LC3B-II in the mdx animal, 
whereas saline treated animals exhibit a low level of LC3B-II expression, even when blocked 
with colchicine.  Scatter plots show results from individual animals. 
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Additional probing of the tibialis anterior (TA) and heart muscle in the 17 month-old mice 
treated for 1 month with RNP was performed to assess the autophagic responses.  Figure 25a 
illustrates significant effects of RNP in TA on p62 (decrease), BNIP3 (increase), and LC3II 
(increase). Figure 25b confirms that RNP also enhanced autophagy in the heart in the same 
manner.  Figure 25c shows autophagic responses to prednisolone in the TA of mdx mice, where 
changes in p62, BNIP3, and LC3II are all similar in direction and magnitude to those reported 
above for RNP, further suggesting that autophagy responses to either RNP or steroids in the mdx 
represents a likely candidate mechanism for the observed augmentation of muscle strength and 
cardiac function. Taken together, these data point to a rapid and widespread induction of 
autophagy in diverse muscle tissues after RNP treatment. 
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Figure 25.  Rapamycin nanoparticles alter autophagic biomarkers in heart and skeletal muscle of 
mdx mice similar to that after steroid therapy. 
a) Tibialis anterior (TA) muscle in 17-month-old mdx mice treated for 1 month with RNP 
exhibited significant effects of RNP on p62 (decrease), BNIP3 (increase), and LC3II (increase). 
b) Cardiac data confirms that RNP also enhance autophagy in the heart in the same manner.  c) 
Young mdx mice given 42 weeks of steroid therapy show similar autophagic responses in the TA 
muscle.  
 
5.5.5. Tissue structural responses 
The amount of collagen within skeletal and cardiac muscles (Figure 26a-d) was not 
different between the treatment groups (p=0.900 for diaphragm using mixed model nested 
ANOVA, p=0.664 for heart using unpaired two-tailed t-test).  Figure 26e demonstrates no 
significant difference between creatine kinase (CK) levels in saline treated animals when 
compared to those treated with NP or RNP (p=0.682, one-way ANOVA).  From these data, it 
does not appear that the nanoparticles are exerting their beneficial effect on strength by altering 
the turnover of myocytes or the replacement of myocytes with collagen in the short term, as 
might be expected after only 8 doses of therapy. 
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Figure 26.  Intravenously injected nanoparticles do not affect short-term muscle cell destruction 
or fibrosis. 
a) Masson trichrome stains performed on diaphragm sections and visualized with light 
microscopy (200x) showed increased fibrosis (blue) for mdx animals relative to WT.  b) No 
significant difference occurred over the short 4 week test interval in mdx collagen levels after 
treatment with either rapamycin-loaded nanoparticles, plain nanoparticles, or saline (mixed 
model nested ANOVA, p=0.90).  c) Picrosirius red stains of mdx mice show diffuse 
heterogeneous fibrosis with d) no significant difference (p=0.664) when treated with RNP. e) 
Serum creatine kinase levels for mdx mice exhibited no significant difference after treatment 
with either RNP, NP, or saline (ANOVA, p=0.71).  All bar graphs show mean values +/- s.d. 
 
5.6. Discussion 
The present findings indicate that rapid improvement in physical performance of either 
skeletal and cardiac muscle can be achieved after only 8 doses of RNP in conjunction with 
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augmented autophagy.  In contrast, oral rapamycin in pharmacological doses exerted no 
significant effect on strength within the same interval.   The observations that the improvement 
in grip strength is repeatable after a drug holiday in the same mice, together offer further support 
for the salutary role of RNP on enhancing autophagy, global physical performance, and cardiac 
function in muscular dystrophy. The muted response to strength testing in aged mdx as compared 
to the clear enhancement in cardiac function reveals a not unexpected limitation on what might 
be achievable after initiation of therapy late in the disease process. 
Recently published work suggests that autophagy induction may be beneficial to mdx animals, 
whether induced by rapamycin or by dietary protein reduction (Pauly, Daussin et al. 2012).  
Moreover, a decrease in autophagic flux in vivo has been previously reported for an animal 
model of Bethlem myopathy and Ullrich congenital muscular dystrophy due to mutations in 
Col6a-/- suggesting that disturbed autophagy might occur in other muscular 
dystrophies (Grumati, Coletto et al.), yet this mechanism has not been evaluated previously for 
aged DMD/mdx, as we show here. Furthermore, no prior studies have demonstrated 
improvements in global physical performance in vivo or cardiac function after rapamycin 
therapy in aged animals that might be attributable to enhanced autophagy. 
The observation of a muted response to short term RNP in the older 17-month-old mice for 
skeletal muscle performance in the face of a clear improvement in myocardial LVEF and clear 
induction of autophagy points out certain divergent pathophysiological features of the disease.  It 
is recognized that the heart disease in DMD appears later than the skeletal muscle weakness, but 
emerges ultimately as a major source of morbidity and mortality. Why heart muscle is relatively 
more resistant to disease progression than is skeletal muscle despite continuous contractile 
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activity remains unknown. Interestingly, the disease in the heart evolves regionally (e.g., 
base>apex) despite the ubiquitous loss of the dystrophin (Chapter 2~3).  
Although recent retrospective analyses of steroids in DMD are highly suggestive of a 
beneficial long-term effect on cardiac function (Schram, Fournier et al. 2013), the present data 
are the first to illustrate such rapid improvement with systemic rapamycin in a prospective trial 
invoking a unique mechanism of action.  Parenthetically, our observation of improved LVEF 
even in wild type subjects (Figure 22) accords with a recent report by Flynn et al. noting better 
LVEF in 24 month-old female nondystrophic animalds treated continuously for 3 months with 
rapamycin in an oral "high delivery" formulation (Flynn, O'Leary et al. 2013). The attenuated 
response of skeletal muscle strength to RNP in older mdx in our study suggests either that longer 
term or more aggressive therapy might be required at this stage to enhance strength, or that 
certain limitations may exist for this (or even any) form of therapy, neither of which is especially 
surprising. Interestingly, Flynn et al also reported that oral rapamycin increased endurance but 
not intensity of activity in 24 month-old female mice, suggesting a muted effect on strength 
improvement in older subjects in general, which accords with our observation on grip strength 
for the 17-month old dystrophic mice (Flynn, O'Leary et al. 2013). Regardless, the ability of 
RNP to rapidly improve cardiac performance suggests that a single agent might be useful.   
 
The cumulative dose of rapamycin administered to the animals in the rapamycin-loaded 
nanoparticle treatment group was within the limits of recommended oral doses for patients 
receiving immunosuppressive therapy when accounting for ~20% oral absorption in humans 
(Ferron, Conway et al. 1997).  The rationale for comparing intravenous nanoparticle rapamycin 
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therapy with oral rapamycin delivery stems from the conventional practice of oral delivery as 
standard of care in patients requiring immune suppression, which is known to be effective and 
well tolerated at the recommended dose levels. We accounted for the well-known and previously 
reported bioavailability for oral dosing (rough estimates: ~10% in mice (Napoli, Wang et al. 
1997; Stepkowski 2003; O'Reilly, McSheehy et al. 2010) by augmenting the doses that were 
delivered to mice by oral gavage to ensure adequate delivery.  Typical clinical maintenance 
dosing for oral delivery of sirolimus in organ-transplant scenarios for body mass greater than 40 
kg is 2 mg/day (Rapamune, Pfizer Inc, Philadelphia, PA). Assuming 20% bioavailability, this 
equates to approximately 0.4 mg of rapamycin in circulation per day, or approximately 0.006 
mg/kg/day for a 70 kg patient. The maximum permissible daily dose of rapamycin is 40 mg, 
which equates to 0.11 mg/kg/day. Mice treated with RNP i.v. in the current study were given 
0.067 mg/kg rapamycin biweekly for a total of 8 times over 4 weeks, or the equivalent of 0.002 
mg/kg/day, within the clinical bounds for regular therapeutic use. 
The intravenous dose used here was approximately 7-fold less than the calculated absorbed 
oral dose administered to mdx mice by Eghtesad and colleagues to improve muscle 
histopathology (Eghtesad, Jhunjhunwala et al.).  Moreover, Eghtesad also reported that oral or 
injected rapamycin exerted no affect on the TA muscle, in contrast to the marked upregulation of 
autophagy reported here in the TA after RNP therapy (see Figure 26). Taken together, these data 
indicate that at clinically relevant doses of oral rapamycin for mdx animals, which scale up to 4–
fold greater than the recommended oral dose for patients, no improvement in skeletal muscle 
strength might be expected.  In contrast, a clinically approved cumulative dose of rapamycin 
administered in NP formulations rapidly elicited marked improvement in both global physical 
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performance and cardiac function after only eight i.v. treatments, which could represent an 
advantage for periodic, short-term dosing. 
Furthermore, nanoparticles alone did not increase autophagic flux in wild-type mice whereas 
rapamycin nanoparticles did.  While rapamycin is known to promote autophagy via an mTOR 
dependent mechanism, the mechanism by which nanoparticles influence autophagy is not known.  
It is intriguing that nanoparticles were unable to enhance autophagy in wild-type mice with 
presumably normal sarcolemmal structure whereas in mdx mice that have defective sarcolemmal 
integrity due to dystrophin mutations, nanoparticles were effective. 
Rapamycin also exhibits mTORC1-independent effects when it binds to FKBP12 on the 
ryanodine receptor.  Previous studies suggest that binding of rapamycin disrupts the ryanodine 
receptor’s functions and therefore would be expected to elicit dysfunctional calcium handling 
(Ahern, Junankar et al. 1997; Avila, Lee et al. 2003).  However, in mdx animals, the ryanodine 
receptor itself appears to be dysfunctional (Bellinger, Reiken et al. 2009).  It may be the case that 
the addition of rapamycin acts to modulate some of these receptors in a favorable manner and 
effect more normal calcium handling or else acts to decrease the expression of the receptors as 
has been previously reported (Avila and Dirksen 2005).  
The effectiveness of nanoparticles and rapamycin nanoparticles for stimulating autophagy in 
mdx mouse muscle mirrors that of their efficacy in rapidly improving grip strength and cardiac 
function. Although these data may not establish absolute proof of cause and effect for the 
relationship between autophagy and strength, they suggest an intriguing candidate mechanism 
for the decline in strength that might be manageable clinically with an approved drug and a new 
delivery system. 
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Although the exact mechanism responsible for rapamycin's entry into muscle tissue remains 
to be clarified, the effect on autophagy is clear and seems dependent on nanoparticle depot 
delivery, because oral therapy is ineffective at the doses that were administered.  The sustained 
presence of nanoparticles and rapamycin in skeletal and cardiac tissues is clear from the 19F 
spectroscopy and the fluorescence imaging data. Prior pharmacokinetic studies in both rabbits 
and mice using PFC nanoparticles have confirmed a clearance halftime (or, elimination half-life) 
of ~3-5 hours in normal mice and rabbits used in various cancer models (Hu 2007; Soman, 
Baldwin et al. 2009), irrespective of molecular targeting, suggesting that there should be ample 
opportunity to penetrate into the damaged tissues. We previously have demonstrated rapid 
permeation of these nanoparticles in other situations where leaky or disrupted vasculature 
pertains, such as advanced atherosclerosis in cholesterol fed rabbits, and even in atherosclerotic 
human carotid endarterectomy specimens (Cyrus, Zhang et al. 2008; Zhang, Zhang et al. 2011). 
It is instructive to note that in dystrophic subjects, recent and prior publications have pointed out 
the widespread vascular dysfunction and damage that permits egress of circulating components 
into muscle interstitium (Vidal, Ardite et al. 2012). Dystrophic subjects also harbor defects in 
vascular endothelium that render lining cells susceptible to apoptosis and impaired angiogenesis 
(Palladino, Gatto et al. 2013), creating a situation of barrier dysfunction that even applies to the 
blood-brain barrier (Lien, Mohanta et al. 2012). 
Regarding the translational potential of this approach, we note that these beneficial effects on 
both heart and skeletal muscle were achieved at a cumulative dose of rapamycin that accords 
with clinically recommended dosing.  Although the side effects of rapamycin on glucose 
tolerance, weight gain, blood pressure, and immune responsiveness are recognized, the drug is 
generally well tolerated over many years by patients with organ transplantation. The fact that 
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both prednisone and rapamycin appear to induce autophagy as a possible mechanism of action 
raises the possibility that the potential deleterious consequences of either agent might be 
mitigated if used in lower doses in combination, or at least if RNP could be employed for a 
steroid sparing action. 
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6.  
Chapter 6: Conclusion 
 
6.1. Summary of major findings 
In this study, we observed that: 
1. Myocardial sheets can be imaged in fresh/unfixed/unstained heart with photoacoustic 
image microscopy, indicating that sheet structures are not just dehydration artifacts as 
criticized in earlier histology studies (Zhang, Cheng et al. 2012).  
2. By using Langendorff perfused heart preparations with DTI, viable myocardial sheet 
function can be imaged without motion-artifact. We observed that sheet dysfunction is 
manifest in diastole but not in systole, indicating a relaxation problem with mdx hearts 
(Chapter 2). 
3. Fibrosis and sheet dysfunction evolve regionally in the mdx mouse heart at the base 
despite the lack of dystrophin in every cardiac cell, indicating that all other observed 
concomitant pathologies contributing mechanistically to the cardiomyopathy are 
secondary and developmental rather than primary drivers of the disease process (Chapter 
2). 
4. Sheet dysfunction is reversible by lowering the perfusate calcium concentration, i.e., mdx 
heart exhibits calcium dependent relaxation-failure (Chapter 2). 
5. At least two tensor invariants are needed to describe the anisotropy of the diffusion tensor, 
although most related research has reported only fractional anisotropy for reasons of 
simplicity.  Here we demonstrate how the mode of anisotropy and fractional anisotropy 
provide complimentary information regarding myocardial architecture anisotropy in mdx 
mice (Chapter 3). 
83 
 
6. Abnormal calcium transients are stretch activated and evolve regionally first at the base, 
indicating that the lack of dystrophin triggers calcium mishandling more quickly at the 
base but not the apex, especially when stretched (Chapter 4). 
7. Fibrosis, sheet dysfunction, and calcium mishandling are all more severe in older mdx 
mice (16 month old) than in young mice (3 month old). 
 
 
6.2. Future works: 
6.2.1. Intervention for calcium mishandling and autophagy in DMD 
In Chapter 2, we found that mdx sheet dysfunction is regional, progressive and calcium 
dependent. Therefore, we hypothesized that if we correct the calcium mishandling, we could 
ameliorate sheet dysfunction. This was carried out in whole hearts by adjusting perfusates with 
good results, which is compatible with other strategies mentioned above to ameliorate calcium 
mishandling and systolic dysfunction by genetically engineered approaches. In the case of sheet 
dysfunction that produces diastolic abnormalities early in the course of heart disease, which itself 
may predispose to further damage by "stiffening" the heart, even earlier metrics of beneficial 
interventions might be observed via restoration of sheet mechanics. Although steroids are 
currently the most effective treatment for DMD patients, their efficacy decreases after prolonged 
treatment (Markham, Spicer et al. 2005). Therefore, cocktail therapies targeting different 
pathological mechanisms with the use of steroids, current calcium approaches, ACEi, autophagy, 
and beta-blockers might be desirable in the hopes that gene therapy might emerge as a first line 
therapy. The proposed DTI measured sheet angle could offer a surrogate for the efficacy of such 
interventions. 
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6.3. Remarks on dystrophin function  
Here it is instructive to quote from other author's insights into the progressive regional nature 
of dystrophin-null cardiomyopathy (Judge, Kass et al. 2011): 
“One hypothesis regarding the cause of cardiomyopathy for individuals with reduced or 
absent dystrophin is based simply on a structural deficiency. Since dystrophin is part of the 
DGC, its primary role may be to hold this complex together. When deficient or absent, the 
dystrophin-associated glycoprotein complex may deteriorate due to the hemodynamic stress 
associated with normal left ventricular function. Evidence for this includes the loss of several 
components of the DGC from the plasmalemma when dystrophin is absent. If this were the 
only contribution of dystrophin to normal cardiac function, then one would anticipate that 
cardiac dysfunction would be more uniform with regard to its age of onset and severity in 
DMD. … Another hypothesis for cardiac dysfunction in DMD and BMD posits that 
dystrophin and its associated complex of ECM glycoproteins play a regulatory role. ” 
Then one might ask, what regulatory function might dystrophin have? And furthermore, why 
would this be different at the base and apex? In fact, nitric oxide, SMAD, or TGF-beta pathways 
all are reported to be affected by dystrophin-null conditions (Chao, Silvagno et al. 1998; 
Heydemann, Ceco et al. 2009; Goldstein, Kelly et al. 2011), but it is still unclear what the role of 
dystrophin in those pathway might be and whether these problems are primary or secondary to 
myocyte damage. For example, does dystrophin turn on NO pathway to increase coronary flow 
in response to certain mechanical input? If dystrophin is a switch, what turns it on in response to 
what stimulus? The function of dystrophin can be discussed from an evolutionary standpoint. 
First, dystrophin is an ancient protein that exists even in drosophila and sea urchin (Neuman, 
Kaban et al. 2001; Kucherenko, Marrone et al. 2011). Morris 1977 found that “In Xenopus heart, 
little or no dystrophin was found on Western blots but the dystrophin-related protein, utrophin, 
was abundant. … In skeletal muscle, however, Xenopus resembles mammals in expressing 
dystrophin at the sarcolemma and very little utrophin” (Morris 1997). Based on the fact that 
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Xenopus, an amphibian, does not express dystrophin in the heart, one could hypothesize that 
dystrophin was adapted in mammal hearts for some unknown function that is not required in 
amphibian hearts. Therefore, a comparative study on heart function and dystrophin distribution 
in base vs apex of the heart could shed lights on dystrophin’s mysterious function. It also would 
be telling to investigate dystrophin’s expression in heart development, especially to focus on 
different locations exhibiting different stress levels in embryological development; and at 
different development stages such as before and after the foramen ovale closes. It is possible that 
cardiac dystrophin’s regional expression may change dramatically as a marked redistribution of 
cardiac stress occurs during and after birth, in light that dystrophin protein was not detected in 
early embryonic days until prenatal stage in rat (Tanaka and Ozawa 1990). 
It also is curious why the apex is spared. Recall the Laplace law (eq41). 
𝑆 =
𝑃
2
 ×
𝑟
ℎ
              …...            eq41 
Stress in the ventricular wall (S) is proportional to transmural pressure (P) and the ratio between 
radius (r) to wall thickness (h) (Warren W. Burggren 1997). Indeed, Kim el al have reported ~30% 
higher wall stress at the base of anesthetized canine heart (Kim, Min et al. 1985). In 1998, using 
markers and intraventricular pressure catheters, DeAnda et al also estimated up to four times 
higher wall stress in base compared to apex in awake dogs (DeAnda, Komeda et al. 1998), 
agreeing with the prediction made with Laplace law. 
Evolution in some respects is an adaptation to stress. 360 Million years ago, fish evolved 
into amphibians and faced new challenges in a terrestrial environment, including air exchange, 
dehydration, and gravity. In water, animal’s body weight is supported by buoyancy, which is not 
operative on land. Therefore, gravity might contribute to the fact that the largest extant land 
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animal, the African bush elephant (4.9 tons, 6m)9, is 22 times lighter than the largest marine 
animal blue whales (110 tons, 25.5m)10. Humans assume that living on the land is simple, but 
living in the ocean is challenging. But in evolution, the ability to deal with the land environment 
is emergent as opposed to encoded.  Indeed, terrestrial animals likely must “pay” for their body 
size with certain limiting adaptations. Because area-dependent functions increase  less  rapidly 
than volume-dependent functions as an organism’s size increase, severe scaling constraints may  
result  as  land organisms evolved to larger size (Schmidt-Nielsen 1984). For example, assuming 
no allometry, body weight is proportional to the body length to the power of three, while the 
muscle cross section area11 is proportional to body length to the power of two. Therefore, the 
stress (force/area) in muscle, in order to bear the body weight of the land animal, is proportional 
to the “body weight divided by muscle cross section area,” which is body length to the power of 
one. Therefore, we might assume that a 180 cm tall man experiences twice the stress in the calf 
as does a 90 cm tall man, all else being equal. 
It is logical then that the fundamental function of dystrophin is to protect muscle in high 
stress environment. Myocardial sheet/calcium transient abnormalities and fibrosis manifest 
more at base but not apex in 16 month old mdx mice (Chapter 2), consistent with higher stress at 
the base than apex (DeAnda, Komeda et al. 1998). Furthermore, myocardial sheet abnormalities 
and fibrosis do not appear in 3 month old mdx mice, which have 15% smaller heart radius. 
Potentially, the smaller radius resulting in smaller stress spares the heart from abnormalities at 
                                                          
9 African bush elephant. Animal Diversity Web. 
http://animaldiversity.ummz.umich.edu/site/accounts/information/Loxodonta_africana.html 
10 Blue Whale. The Marine Mammal Center. http://www.marinemammalcenter.org/education/marine-mammal-
information/cetaceans/blue-whale.html#.UjIVGcZ6ZRs 
11 Vertebrate striated muscle  exerts  nearly  a  constant peak tensile stress, ~200k Pa = 2M dyn/cm2, among 
species. Biewener, A. A. (1989). "Scaling body support in mammals: limb posture and muscle mechanics." Science 
245(4913): 45-48. 
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earlier ages. Therefore, young mice do not exhibit a cardiac, or even much skeletal dystrophic 
phenotype, despite the fact that all tissues lack dystrophin before birth.  
 DMD patients (dystrophin-null) experience the onset of symptoms before two year old 
and become wheelchair bounded between ages 7 and 13. On the other hand, BMD patients 
(dystrophin-deficient) have much more benign progress of disease. BMD patients have their 
onset of symptoms between ages 2 to 21, and become wheelchair bound between ages 22 and 51 
(Emery and Skinner 1976). That is, the partially expressed dystrophin in BMD patients is still 
able to protect the increased stress from the growing body size until age 22 to 51. In a 111 DMD 
patients study, height was found to be correlated with disease progression (disability accessed by 
the Vignose scale) with a correlation coefficient of 0.352 (p<0.001), indicating that small stature 
might protect against the ravages of  DMD. A classic paper that has been cited 870 times has 
reported sarcolemma damage is linearly correlated with stress (force/area cross section). That is, 
mdx diaphragm muscle shows more damage than does wildtype diaphragm muscle (Petrof, 
Shrager et al. 1993). Similarly, cardiomyocytes of mdx mice are more vulnerable to mechanical 
stress induced by isoproterenol and aortic banding (Danialou, Comtois et al. 2001) than are 
normal myocytes. Indeed, anti human growth hormone (HGH) therapy was found to be effective 
in DMD patients (Zatz, Betti et al. 1986). Four case reports suggested that patients with 
deficiency in both HGH and dystrophin show slow or no progress of muscular waste until the 
administered to solve the short stature (Zatz, Betti et al. 1981; Zatz and Betti 1986; Ghafoor, 
Mahmood et al. 2003; Calcaterra, Malvezzi et al. 2013). However, an HGH inhibitor, mazindol, 
fails to inhibit the growth over longer times as suggested by Zatz (Zatz, Rapaport et al. 1988): 
“However, the recent report of two new DMD patients with short stature and a  benign  
evolution  of  the  dystrophic process (Passos et al., 1988; Wu et al., 1988) and the 
observation of  wide variability in the progression  of the disease in DMD/BMD patients 
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with apparently the same  DNA  deletions  suggests  that  secondary  factors, such as 
growth hormone (GH) may be implicated in the progression of the disease  (Infante and  
Huszagh,  1988; Malhotra  et  al., 1988).” 
That is, Zatz speculated GH itself might have modified the disease. It appears rather more 
likely that the GHheightstress cascade is the operative factor in modifying the disease. 
It is known that, in DMD patients, calf muscles fail to perform normal function first, then 
the diaphragm fails (Bach 1992; Hamada, Ishikawa et al. 2011). The cardiomyopathy emerges 
last (Fayssoil, Nardi et al. 2010). It is natural to ask: among the calf, the diaphragm, and the heart, 
which muscle bears the most stress (force/area)? Does the failure sequence in DMD muscles 
correspond to the ranking of stress? To the best of my knowledge, there is no study comparing 
stresses in these three muscles together in DMD nor in mdx mice. However, the following 
summarizes the existing data. 
Thorpe et al found normal young adults (~1.7m ~73kg) have peak stresses of 100 kNm-2 
during high jumps and 150kNm-2 during 4ms-1 running in calf (gastrocnemius and the soleus) 
(Thorpe, Li et al. 1998). Using the reported height of age 8 DMD patients, ~1.4m (Beenakker, de 
Vries et al. 2002), and assuming no allometry and stress is roughly proportional to the height, we 
can estimate the high jump and running stress in a DMD boy are 82 and 123 kN/m2 , 
respectively, which should be the upper limit of stress in DMD patient calf, because they have 
pseudo-hypertrophic calf and less contractility due to fibrosis. 
Stress data in calf muscles in a standing posture in normal humans are scanty. However, 
Morse et al have reported isometric maximum stress of calf muscles in young (131 kN/m2 , age 
25, 1.7m, 79 kg ) and elderly (92 kN/m2 , age 74, 1.7 m, 78 kg) normal people (Morse, Thom et 
al. 2005). Taking elderly subjects stress data and assuming no allometry, a DMD patient of 1.4 m 
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height should have an isometric maximum stress of 92*1.4/1.7= 75 kN/m2 in calf. Although 
assuming no allometry may not be true, it is the best approximation devoid of additional calf 
geometry information. I cannot find any literature addressing the fascicle force and physiological 
cross-sectional area in calf muscles of DMD patients. However, from the above two literature 
sources, I estimate that standing calf stress in DMD patient is smaller than 75 kN/m2. 
mdx mice diaphragm strips were reported to exert maximum tetanic stress of 91~136 
kN/m2  in ex vivo experiment (Lynch, Rafael et al. 1997; Lynch, Hinkle et al. 2001). In vivo 
measurement of diaphragm stress were not available in literature, to the best of my knowledge, 
probably because the thin anatomical geometry of the diaphragm limits the observation 
opportunity. However, Hughes et al used two balloons placed in the stomach and esophagus to 
measure the transdiaphragmatic pressure in normal adult humans and reported a value of 143 cm 
H2O (105 mmHg) (Hughes, Polkey et al. 1999). Meanwhile, Beck reported a maximum 
transdiaphragmatic pressure of 7.6 cmH2O ( 5.6 mmHg ) in DMD patients with advanced stage 
disease (N=8, mean age 25) (Beck, Weinberg et al. 2006). Although the in vivo stress of the 
diaphragm was not reported, it is not unreasonable to assume that the diaphragm exhibits 
comparable or higher stress than does heart wall, because the thickness of diaphragm (1.74 mm 
thick in 10 year old DMD patients; 1.45 mm in normal controls (De Bruin, Ueki et al. 1997)) 
is >3 times thinner than heart wall ( 4.8 mm in diastole; 8.7 mm in systole (Goldberg, Feldman et 
al. 1980)). Diaphragm has comparable maximal transmural pressure as with the heart (105 
mmHg vs 120mmHg). Meanwhile, the diaphragm has much larger radius of curvature. 
Numerical values of stress in normal adult human heart wall are more abundant. Normal 
wall stress was reported to be 18~33 kN/m2 in systole and 2~3 kN/m2 in diastole (Hood, Rackley 
et al. 1968; Grossman, Jones et al. 1975). In DMD, one study reported 23 DMD patients with 
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mean age of 8 have a wall stress of 49 (Markham, Kinnett et al. 2008). Unfortunately. this paper 
ignored the units of wall stress.   
In conclusion, values from literature suggest that the calf might be stressed more in 1.4m 
tall boys than the heart (75 vs 18~49 kN/m2). I speculate that the diaphragm might experience 
even higher stresses than the heart because of the comparable transmural pressures in the face of 
thinner thickness, and larger curvature radius, but there are no available data reported. After 
reviewing all of the published values of stresses, it would not be surprising if the stress ranking is 
actually: calf > diaphragm > heart, which might explain the temporal sequence of failing muscles 
in DMD patients. 
Deconinck proposed a damage pathway 
initiating with the lack of dystrophin (Figure 27) 
(Deconinck and Dan 2007). However, this simplistic 
model fails to incorporate the supposition that it might 
be stress itself that modifies the degree of damage in 
different parts of the heart and skeletal muscles at 
different ages and body sizes. 
 
 
 
 
 
Figure 27. mdx dystrophy pathway proposed by 
Deconinck et al. (Deconinck and Dan 2007) 
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Hauser, Whitehead, and Yeung suggested that “NADPH oxidase is a major source of 
reactive oxygen species in dystrophic muscle and its enhanced activity has a stimulatory effect 
on stretch-induced Ca2+ entry, a key mechanism for muscle damage and functional impairment.” 
(Hauser, Hoger et al. 1995; Whitehead, Yeung et al. 2010; Yang, Chin et al. 2013) That is, these 
authors have recognized the stretch-induced damage is a factor complementing the lack of 
dystrophin. Therefore, I propose an updated damage pathway in Figure 28, proposing that the 
stress in muscle is the activation factor operating on the ubiquitous lack of dystrophin.  
 
Figure 28.  Hypothesized mdx dystrophy pathway. 
 
To ameliorate DMD, beta blockers, ACE inhibitors, and growth inhibition have all been 
reported to slow DMD progression (Zatz, Betti et al. 1986). In the hypothesis proposed in this 
Chapter, these therapies work because they all modulate stresses in muscles. However, none of 
these can have a long-term curative effect, leaving more revolutionary genetic and 
pharmaceutical strategies desirable.  
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7.  
Appendices 
 
Principle of MRI 
 
-Physics 
In the view of classic physics, hydrogen nuclear spins, and thus creates magnetic moment, 
which aligns to surrounding magnetic field (B0) in the same way compass points to the North 
Pole. 12 Instead of aligning statically with B0, the magnetic moment would precess about the B0 
direction. The precession frequency, ω, is named Larmor Frequency and defined by ω = γ B, 
where γ is gyromagetic ratio, depending on nuclear species. While nuclei spin reaches steady 
state of precession toward B0, we can excite the steady state temporarily with an added magnetic 
field (B1), causing the nuclear spin to deviate from its steady state orientation.
13 After the B1 was 
stopped, nuclear spin will align back to the B0 direction and release energy in a form of 
detectable radio frequency magnetic waves (called free induction decay, FID), which can be 
recorded and signal processed for imaging purposes. 
 
-Imaging 
Invented in 1952, MRI allows scientist to acquire FID and forms images to provide 
structural and functional information. Recall the Larmor Frequency, ω = γ B, which is 
proportional to the magnetic field strength B, allowing us to control the ω by varying the B. For 
imaging purpose, we are interested in encode spin at different spatial locations with different ω. 
Therefore, a gradient of magnetic field, Gx, was applied along x direction on top of the B0, 
making the ω a function of x, that is, ω(x)=B0  + x ·G, therefore, the recorded FID carries spatial 
information in different frequencies, allowing imaging reconstruction through inverse Fourier 
transform. This imaging technique is called frequency encoding. Please refer to book in footnote 
11 for more information. By turning on-off radio frequency pulses and gradients at specific time 
and direction, we would be able to form images to suit specific purpose. The specific 
timing/direction/strength of radio frequency pulses and gradients are call pulse sequence, which 
determines the sources of contrast and properties of the images. 
  
                                                          
12 The mechanism of nuclear spin is beyond scope, please refer to “Questions and Answers in Magnetic Resonance 
Imaging”, 2000, by Allen D. Elster. 
13 For detailed physics explanation, see “Spin Dynamics: Basics of Nuclear Magnetic Resonance” by Malcolm H. 
Levitt (2008) 
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Supplemental tables 
 
Table 2.Post Hoc Multiple Comparisons of |β| in 16 month old mice 
Bonferroni 
Dependent Variable (I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
magB_slc1 1 2 2.4033 2.01043 1.000 -3.6447 8.4514 
3 1.0321 2.01043 1.000 -5.0159 7.0802 
4 6.7905* 2.01043 .023 .7425 12.8386 
2 1 -2.4033 2.01043 1.000 -8.4514 3.6447 
3 -1.3712 2.01043 1.000 -7.4193 4.6768 
4 4.3872 2.01043 .266 -1.6608 10.4353 
3 1 -1.0321 2.01043 1.000 -7.0802 5.0159 
2 1.3712 2.01043 1.000 -4.6768 7.4193 
4 5.7584 2.01043 .067 -.2896 11.8065 
4 1 -6.7905* 2.01043 .023 -12.8386 -.7425 
2 -4.3872 2.01043 .266 -10.4353 1.6608 
3 -5.7584 2.01043 .067 -11.8065 .2896 
magB_slc2 1 2 -.6827 2.36177 1.000 -7.7877 6.4223 
3 -1.3088 2.36177 1.000 -8.4138 5.7962 
4 4.9628 2.36177 .311 -2.1422 12.0677 
2 1 .6827 2.36177 1.000 -6.4223 7.7877 
3 -.6261 2.36177 1.000 -7.7311 6.4789 
4 5.6455 2.36177 .177 -1.4595 12.7504 
3 1 1.3088 2.36177 1.000 -5.7962 8.4138 
2 .6261 2.36177 1.000 -6.4789 7.7311 
4 6.2715 2.36177 .104 -.8334 13.3765 
4 1 -4.9628 2.36177 .311 -12.0677 2.1422 
2 -5.6455 2.36177 .177 -12.7504 1.4595 
3 -6.2715 2.36177 .104 -13.3765 .8334 
magB_slc3 1 2 -.9798 2.26177 1.000 -7.7840 5.8244 
3 -.3786 2.26177 1.000 -7.1828 6.4255 
4 8.3630* 2.26177 .012 1.5588 15.1672 
2 1 .9798 2.26177 1.000 -5.8244 7.7840 
3 .6012 2.26177 1.000 -6.2030 7.4053 
4 9.3428* 2.26177 .005 2.5387 16.1470 
3 1 .3786 2.26177 1.000 -6.4255 7.1828 
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2 -.6012 2.26177 1.000 -7.4053 6.2030 
4 8.7416* 2.26177 .008 1.9375 15.5458 
4 1 -8.3630* 2.26177 .012 -15.1672 -1.5588 
2 -9.3428* 2.26177 .005 -16.1470 -2.5387 
3 -8.7416* 2.26177 .008 -15.5458 -1.9375 
magB_slc4 1 2 -1.3733 2.27890 1.000 -8.2290 5.4824 
3 -.3664 2.27890 1.000 -7.2221 6.4893 
4 5.1555 2.27890 .228 -1.7002 12.0112 
2 1 1.3733 2.27890 1.000 -5.4824 8.2290 
3 1.0069 2.27890 1.000 -5.8488 7.8626 
4 6.5288 2.27890 .067 -.3269 13.3845 
3 1 .3664 2.27890 1.000 -6.4893 7.2221 
2 -1.0069 2.27890 1.000 -7.8626 5.8488 
4 5.5219 2.27890 .166 -1.3338 12.3776 
4 1 -5.1555 2.27890 .228 -12.0112 1.7002 
2 -6.5288 2.27890 .067 -13.3845 .3269 
3 -5.5219 2.27890 .166 -12.3776 1.3338 
magB_slc5 1 2 .4927 1.96992 1.000 -5.4334 6.4189 
3 .3064 1.96992 1.000 -5.6198 6.2325 
4 5.6741 1.96992 .065 -.2520 11.6003 
2 1 -.4927 1.96992 1.000 -6.4189 5.4334 
3 -.1863 1.96992 1.000 -6.1125 5.7398 
4 5.1814 1.96992 .109 -.7448 11.1076 
3 1 -.3064 1.96992 1.000 -6.2325 5.6198 
2 .1863 1.96992 1.000 -5.7398 6.1125 
4 5.3677 1.96992 .090 -.5584 11.2939 
4 1 -5.6741 1.96992 .065 -11.6003 .2520 
2 -5.1814 1.96992 .109 -11.1076 .7448 
3 -5.3677 1.96992 .090 -11.2939 .5584 
magB_slc6 1 2 1.4707 2.06307 1.000 -4.7357 7.6771 
3 1.4960 2.06307 1.000 -4.7104 7.7025 
4 4.2457 2.06307 .338 -1.9607 10.4521 
2 1 -1.4707 2.06307 1.000 -7.6771 4.7357 
3 .0253 2.06307 1.000 -6.1811 6.2317 
4 2.7750 2.06307 1.000 -3.4314 8.9814 
3 1 -1.4960 2.06307 1.000 -7.7025 4.7104 
2 -.0253 2.06307 1.000 -6.2317 6.1811 
4 2.7497 2.06307 1.000 -3.4567 8.9561 
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4 1 -4.2457 2.06307 .338 -10.4521 1.9607 
2 -2.7750 2.06307 1.000 -8.9814 3.4314 
3 -2.7497 2.06307 1.000 -8.9561 3.4567 
magB_slc7 1 2 2.7587 3.21547 1.000 -6.9145 12.4319 
3 1.1879 3.21547 1.000 -8.4853 10.8611 
4 3.6151 3.21547 1.000 -6.0581 13.2883 
2 1 -2.7587 3.21547 1.000 -12.4319 6.9145 
3 -1.5708 3.21547 1.000 -11.2440 8.1024 
4 .8564 3.21547 1.000 -8.8168 10.5296 
3 1 -1.1879 3.21547 1.000 -10.8611 8.4853 
2 1.5708 3.21547 1.000 -8.1024 11.2440 
4 2.4272 3.21547 1.000 -7.2460 12.1004 
4 1 -3.6151 3.21547 1.000 -13.2883 6.0581 
2 -.8564 3.21547 1.000 -10.5296 8.8168 
3 -2.4272 3.21547 1.000 -12.1004 7.2460 
magB_slc8 1 2 6.8267 5.77138 1.000 -10.5356 24.1889 
3 1.4031 5.77138 1.000 -15.9591 18.7654 
4 8.6303 5.77138 .926 -8.7320 25.9925 
2 1 -6.8267 5.77138 1.000 -24.1889 10.5356 
3 -5.4235 5.77138 1.000 -22.7858 11.9387 
4 1.8036 5.77138 1.000 -15.5586 19.1659 
3 1 -1.4031 5.77138 1.000 -18.7654 15.9591 
2 5.4235 5.77138 1.000 -11.9387 22.7858 
4 7.2271 5.77138 1.000 -10.1351 24.5894 
4 1 -8.6303 5.77138 .926 -25.9925 8.7320 
2 -1.8036 5.77138 1.000 -19.1659 15.5586 
3 -7.2271 5.77138 1.000 -24.5894 10.1351 
 
 
Table 2. Post hoc multiple comparisons for diastolic |β| of 16 month old mdx and WT mice.  
Group1,2,3, and 4 are WT-LC, WT-NC, mdx-LC, and mdx-NC respectively. MagB, |β|. Slc1 is 
base. Slc8 is apex. *, p <  0.05 level. Bonferroni correction. Most differences exist in the slc3 of 
group 4, indicating abnormal |β| manifest closer to base than apex. 
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Table 3. Post Hoc Multiple Comparisons of |β| in 3 month old mice 
Bonferroni 
Dependent Variable (I) group (J) group 
Mean Difference 
(I-J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
magB_slc1 1 2 -1.1000 2.97694 1.000 -10.0556 7.8556 
3 .3200 2.97694 1.000 -8.6356 9.2756 
4 2.4000 2.97694 1.000 -6.5556 11.3556 
2 1 1.1000 2.97694 1.000 -7.8556 10.0556 
3 1.4200 2.97694 1.000 -7.5356 10.3756 
4 3.5000 2.97694 1.000 -5.4556 12.4556 
3 1 -.3200 2.97694 1.000 -9.2756 8.6356 
2 -1.4200 2.97694 1.000 -10.3756 7.5356 
4 2.0800 2.97694 1.000 -6.8756 11.0356 
4 1 -2.4000 2.97694 1.000 -11.3556 6.5556 
2 -3.5000 2.97694 1.000 -12.4556 5.4556 
3 -2.0800 2.97694 1.000 -11.0356 6.8756 
magB_slc2 1 2 -.6400 3.36391 1.000 -10.7598 9.4798 
3 2.0400 3.36391 1.000 -8.0798 12.1598 
4 3.7400 3.36391 1.000 -6.3798 13.8598 
2 1 .6400 3.36391 1.000 -9.4798 10.7598 
3 2.6800 3.36391 1.000 -7.4398 12.7998 
4 4.3800 3.36391 1.000 -5.7398 14.4998 
3 1 -2.0400 3.36391 1.000 -12.1598 8.0798 
2 -2.6800 3.36391 1.000 -12.7998 7.4398 
4 1.7000 3.36391 1.000 -8.4198 11.8198 
4 1 -3.7400 3.36391 1.000 -13.8598 6.3798 
2 -4.3800 3.36391 1.000 -14.4998 5.7398 
3 -1.7000 3.36391 1.000 -11.8198 8.4198 
magB_slc3 1 2 .0600 3.60697 1.000 -10.7910 10.9110 
3 2.1800 3.60697 1.000 -8.6710 13.0310 
4 6.1800 3.60697 .636 -4.6710 17.0310 
2 1 -.0600 3.60697 1.000 -10.9110 10.7910 
3 2.1200 3.60697 1.000 -8.7310 12.9710 
4 6.1200 3.60697 .655 -4.7310 16.9710 
3 1 -2.1800 3.60697 1.000 -13.0310 8.6710 
2 -2.1200 3.60697 1.000 -12.9710 8.7310 
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4 4.0000 3.60697 1.000 -6.8510 14.8510 
4 1 -6.1800 3.60697 .636 -17.0310 4.6710 
2 -6.1200 3.60697 .655 -16.9710 4.7310 
3 -4.0000 3.60697 1.000 -14.8510 6.8510 
magB_slc4 1 2 .1200 3.07448 1.000 -9.1290 9.3690 
3 4.0600 3.07448 1.000 -5.1890 13.3090 
4 7.4600 3.07448 .165 -1.7890 16.7090 
2 1 -.1200 3.07448 1.000 -9.3690 9.1290 
3 3.9400 3.07448 1.000 -5.3090 13.1890 
4 7.3400 3.07448 .178 -1.9090 16.5890 
3 1 -4.0600 3.07448 1.000 -13.3090 5.1890 
2 -3.9400 3.07448 1.000 -13.1890 5.3090 
4 3.4000 3.07448 1.000 -5.8490 12.6490 
4 1 -7.4600 3.07448 .165 -16.7090 1.7890 
2 -7.3400 3.07448 .178 -16.5890 1.9090 
3 -3.4000 3.07448 1.000 -12.6490 5.8490 
magB_slc5 1 2 -1.0200 3.33267 1.000 -11.0458 9.0058 
3 2.5000 3.33267 1.000 -7.5258 12.5258 
4 5.6200 3.33267 .667 -4.4058 15.6458 
2 1 1.0200 3.33267 1.000 -9.0058 11.0458 
3 3.5200 3.33267 1.000 -6.5058 13.5458 
4 6.6400 3.33267 .382 -3.3858 16.6658 
3 1 -2.5000 3.33267 1.000 -12.5258 7.5258 
2 -3.5200 3.33267 1.000 -13.5458 6.5058 
4 3.1200 3.33267 1.000 -6.9058 13.1458 
4 1 -5.6200 3.33267 .667 -15.6458 4.4058 
2 -6.6400 3.33267 .382 -16.6658 3.3858 
3 -3.1200 3.33267 1.000 -13.1458 6.9058 
magB_slc6 1 2 -.3800 3.73493 1.000 -11.6159 10.8559 
3 2.8400 3.73493 1.000 -8.3959 14.0759 
4 4.8800 3.73493 1.000 -6.3559 16.1159 
2 1 .3800 3.73493 1.000 -10.8559 11.6159 
3 3.2200 3.73493 1.000 -8.0159 14.4559 
4 5.2600 3.73493 1.000 -5.9759 16.4959 
3 1 -2.8400 3.73493 1.000 -14.0759 8.3959 
2 -3.2200 3.73493 1.000 -14.4559 8.0159 
4 2.0400 3.73493 1.000 -9.1959 13.2759 
4 1 -4.8800 3.73493 1.000 -16.1159 6.3559 
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2 -5.2600 3.73493 1.000 -16.4959 5.9759 
3 -2.0400 3.73493 1.000 -13.2759 9.1959 
magB_slc7 1 2 -.2000 3.96679 1.000 -12.1334 11.7334 
3 1.8000 3.96679 1.000 -10.1334 13.7334 
4 .6800 3.96679 1.000 -11.2534 12.6134 
2 1 .2000 3.96679 1.000 -11.7334 12.1334 
3 2.0000 3.96679 1.000 -9.9334 13.9334 
4 .8800 3.96679 1.000 -11.0534 12.8134 
3 1 -1.8000 3.96679 1.000 -13.7334 10.1334 
2 -2.0000 3.96679 1.000 -13.9334 9.9334 
4 -1.1200 3.96679 1.000 -13.0534 10.8134 
4 1 -.6800 3.96679 1.000 -12.6134 11.2534 
2 -.8800 3.96679 1.000 -12.8134 11.0534 
3 1.1200 3.96679 1.000 -10.8134 13.0534 
 
Table 3 Post hoc multiple comparisons for diastolic |β| of 3 month old mdx and WT mice 
showing no significance.  
Group1,2,3, and 4 are WT-LC, WT-NC, mdx-LC, and mdx-NC respectively. MagB, |β|. Slc1 is 
base. Slc7 is apex. No significance was found among all comparison. 
 
Speculation: Might low gravity ameliorate dystrophy? 
In the Chapter 4, we raised the point that higher stress within certain muscles might 
explain the regional heterogeneity of dystrophy (e.g., severe at heart base but not apex; severe in 
calf but not forearm). If genetic therapy could not break limitations on gene size and achieve 
stable transfection, relocating DMD patients to low gravity environments might reduce muscle 
stress and ameliorate the dystrophy. Furthermore, low gravity affects normal human health due 
to the redistribution of circulation pressure and decrease muscle/skeleton tension (Smith, McCoy 
et al. 2012). Lower limb muscles atrophy was observed among astronauts to the greatest extent, 
with the calf muscles being most affected and most difficult to target with exercise 
countermeasures (Lester, Standley et al. 2013). Similarly, the most obvious pathological sign of 
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DMD patients is the pseudo-hypertrophic calf muscle, indicating the calf muscle are sensitive to 
stress, both in space and on the Earth. In fact, DMD patients on the Earth and astronauts in orbits 
show complimentary loss of muscle fiber types. Specifically, DMD patients lose fast fibers 
rather than slow fibers (Webster, Silberstein et al. 1988), while astronauts lose slow fibers rather 
than fast fiber (Riley, Bain et al. 2002). I hypothesize that dystrophin is part of stress sensing 
pathway and signals to reduce astronauts’ slow fibers in response to the lower load. When 
dystrophin is missing, the presumed stress sensing pathway might over-react to the normal stress 
on the earth and signal to reduce fast fibers in DMD. Since it is unknown how exactly low-
gravity changes circulation/muscle/skeleton 14, how dystrophin-null animals adapt low-gravity 
environment may shed lights on such mechanism and bring better solutions to counter atrophy in 
space missions. The hypothetical mechanical sensing and protective mechanism of dystrophin 
would be critical for extraplanetary exploration, when we would need to fine-tune human body 
to adapt different gravities.  
Sources of funding:  
American Heart Association 12PRE9310044 (Cheng),  R01 AR056223 (Wickline) 
  
                                                          
14 “The exact cellular and biochemical events that produce these losses of mass and strength are not as well 
understood.” NASA 2013. Effect of Prolonged Space Flight on Human Skeletal Muscle (Biopsy) 
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